WO2013006479A2 - Mammalian cell culture - Google Patents

Mammalian cell culture Download PDF

Info

Publication number
WO2013006479A2
WO2013006479A2 PCT/US2012/045070 US2012045070W WO2013006479A2 WO 2013006479 A2 WO2013006479 A2 WO 2013006479A2 US 2012045070 W US2012045070 W US 2012045070W WO 2013006479 A2 WO2013006479 A2 WO 2013006479A2
Authority
WO
WIPO (PCT)
Prior art keywords
perfusion
asparagine
culture
cell
serum
Prior art date
Application number
PCT/US2012/045070
Other languages
French (fr)
Other versions
WO2013006479A3 (en
Inventor
Brian D. Follstad
Rebecca E. Mccoy
Arvia E. Morris
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46579326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2013006479(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020237024499A priority Critical patent/KR20230114317A/en
Priority to US14/127,050 priority patent/US11292829B2/en
Priority to BR122021007265-5A priority patent/BR122021007265B1/en
Priority to IL310968A priority patent/IL310968A/en
Priority to CN201711406697.2A priority patent/CN107988166B/en
Priority to EA201391826A priority patent/EA039023B1/en
Priority to MX2013014937A priority patent/MX351974B/en
Priority to AU2012279230A priority patent/AU2012279230B2/en
Priority to JP2014519184A priority patent/JP5897708B2/en
Priority to CA2838695A priority patent/CA2838695C/en
Priority to SI201230945A priority patent/SI2726600T1/en
Priority to KR1020187012639A priority patent/KR102108663B1/en
Priority to KR1020167015700A priority patent/KR101857380B1/en
Priority to PL14187232T priority patent/PL2837680T3/en
Priority to IL297998A priority patent/IL297998B2/en
Priority to KR1020147001985A priority patent/KR101662412B1/en
Priority to EP12738674.6A priority patent/EP2726600B1/en
Priority to KR1020237043604A priority patent/KR20240005106A/en
Priority to CN201280032874.4A priority patent/CN103827292B/en
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority to DK12738674.6T priority patent/DK2726600T3/en
Priority to BR112013033730-3A priority patent/BR112013033730B1/en
Priority to ES12738674.6T priority patent/ES2625045T3/en
Priority to KR1020227003428A priority patent/KR102558247B1/en
Priority to IL288509A priority patent/IL288509B2/en
Priority to KR1020207012533A priority patent/KR102358951B1/en
Priority to LTEP12738674.6T priority patent/LT2726600T/en
Priority to EP14187232.5A priority patent/EP2837680B1/en
Publication of WO2013006479A2 publication Critical patent/WO2013006479A2/en
Publication of WO2013006479A3 publication Critical patent/WO2013006479A3/en
Priority to IL229803A priority patent/IL229803B/en
Priority to ZA2013/09372A priority patent/ZA201309372B/en
Priority to HK14110449A priority patent/HK1197081A1/en
Priority to CY20171100366T priority patent/CY1118863T1/en
Priority to CY20201100473T priority patent/CY1123146T1/en
Priority to US17/018,564 priority patent/US11673941B2/en
Priority to US17/018,557 priority patent/US11634476B2/en
Priority to IL278430A priority patent/IL278430B/en
Priority to US17/686,766 priority patent/US20220185869A1/en
Priority to US18/066,251 priority patent/US11685772B2/en
Priority to US18/068,922 priority patent/US20230129523A1/en
Priority to US18/180,828 priority patent/US11827692B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0037Serum-free medium, which may still contain naturally-sourced components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0604Whole embryos; Culture medium therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/02Atmosphere, e.g. low oxygen conditions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/99Serum-free medium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00Culture process characterised by temperature

Definitions

  • the invention provides a method for culturing mammalian cells.
  • the method provides greater control over cell growth to achieve high product titer cell cultures.
  • New cell culture methods that provide even incremental improvements in recombinant protein production are valuable, given the expense of large scale cell culture processes and the growing demand for greater quantities of and lower costs for biological products.
  • the invention fulfills these needs by providing a simple, easy and inexpensive method of controlling cell growth while increasing protein production.
  • the present invention provides a method of arresting cell growth in a mammalian cell culture expressing a recombinant protein comprising establishing a mammalian cell culture in a serum-free culture medium in a bioreactor; inducing cell growth-arrest by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less; maintaining the mammalian cells in a growth-arrested state by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less.
  • the present invention also provides a method of increasing recombinant protein production in a mammalian cell culture expressing a recombinant protein comprising establishing a mammalian cell culture in a serum-free culture medium in a bioreactor; inducing cell growth-arrest by perfusion with a serum-free perfusion medium having an L- asparagine concentration of 5mM or less; maintaining the mammalian cells in a growth- arrested state by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less.
  • recombinant protein production in the mammalian cell culture is increased compared to a culture where the cells are not subjected to L-asparagine-induced cell growth-arrest.
  • the present invention also provides a method of limiting a mammalian cell culture expressing a recombinant protein at a desired packed cell volume comprising establishing a mammalian cell culture in a serum- free culture medium in a bioreactor; inducing cell growth- arrest by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less; maintaining the mammalian cells in a growth-arrested state by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less.
  • any of the methods above begins on or before day 3 of the culture.
  • in any of the methods above induction of cell growth-arrest takes place prior to a production phase.
  • in any of the methods above induction of cell growth-arrest takes place during a production phase.
  • in any of the methods above cell growth- arrest is induced by L-asparagine starvation.
  • any of the methods above further comprise a temperature shift from 36°C to 31°C.
  • any of the methods above further comprise a temperature shift from 36°C to 33°C.
  • the temperature shift occurs at the transition between a growth phase and a production phase. In yet another embodiment the temperature shift occurs during a production phase. In another embodiment the methods above further comprise a packed cell volume during a production phase less than or equal to 35%. In a related embodiment the packed cell volume during a production phase is less than or equal to 35%
  • the present invention also provides a method of culturing mammalian cells expressing a recombinant protein comprising; establishing a mammalian cell culture in a serum-free culture medium in a bioreactor; growing the mammalian cells during a growth phase and supplementing the culture medium with bolus feeds of a serum-free feed medium, and maintaining the mammalian cells during a production phase by perfusion with a serum- free perfusion medium, wherein the packed cell volume during the production phase is less than or equal to 35%.
  • perfusion begins on or about day 5 to on or about day 9 of the cell culture. In a related embodiment perfusion begins on or about day 5 to on or about day 7 of the cell culture.
  • perfusion begins when the cells have reached a production phase.
  • the method further comprises inducing cell growth-arrest by L-asparagine starvation followed by perfusion with a serum- free perfusion medium having an L-asparagine concentration of 5 mM or less.
  • the method further comprises inducing cell growth-arrest by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5 mM or less.
  • the concentration of L-asparagine in the serum- free perfusion medium is less than or equal to 5mM.
  • the concentration of L-asparagine in the serum-free perfusion medium is less than or equal to 4.0 mM.
  • the concentration of L-asparagine in the serum-free perfusion medium is less than or equal to 3.0 mM. In still another embodiment the concentration of L- asparagine in the serum-free perfusion medium is less than or equal to 2.0 mM. In yet another embodiment the concentration of L-asparagine in the serum-free perfusion medium is less than or equal to 1.0 mM. In yet another embodiment the concentration of L-asparagine in the serum-free perfusion medium is 0 mM. In another embodiment perfusion is performed at a rate that increases during the production phase from 0.25 working volume per day to 1.0 working volume per day during the cell culture.
  • perfusion is performed at a rate that reaches 1.0 working volume per day on day 9 to day 11 of the cell culture. In another related embodiment perfusion is performed at a rate that reaches 1.0 working volume per day on day 10 of the cell culture. In yet another embodiment the bolus feeds of serum- free feed medium begin on day 3 or day 4 of the cell culture.
  • the method further comprises a temperature shift from 36°C to 31°C. In another embodiment the method further comprises a temperature shift from 36°C to 33°C. In a related embodiment the temperature shift occurs at the transition between the growth phase and production phase. In a related embodiment the temperature shift occurs during the production phase.
  • the L-asparagine concentration of the cell culture medium is monitored prior to and during L-asparagine starvation.
  • the packed cell volume is less than or equal to 35%. In a related embodiment the packed cell volume is less than or equal to 30%.
  • the viable cell density of the mammalian cell culture at a packed cell volume less than or equal to 35 % is lOxlO 6 viable cells/ml to 80xl0 6 viable cells/ml. In a related embodiment the viable cell density of the mammalian cell culture is 20x10 6 viable cells/ml to 30xl0 6 viable cells/ml.
  • perfusion comprises continuous perfusion.
  • the rate of perfusion is constant.
  • perfusion is performed at a rate of less than or equal to 1.0 working volumes per day.
  • the mammalian cell culture is established by inoculating the bioreactor with at least 0.5 x 10 6 to 3.0 x 10 6 cells/mL in a serum-free culture medium.
  • the mammalian cell culture is established by inoculating the bioreactor with at least 0.5 x 10 6 to 1.5 x 10 6 cells/mL in a serum- free culture medium.
  • the perfusion is accomplished by alternating tangential flow.
  • the bioreactor has a capacity of at least 500L. In a related embodiment the bioreactor has a capacity of at least 500L to 2000L. In yet another related embodiment the bioreactor has a capacity of at least 1000L to 2000L.
  • the recombinant protein is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a recombinant fusion protein, or a cytokine.
  • any of the methods above further comprise a step of harvesting the recombinant protein produced by the cell culture.
  • the recombinant protein produced by the cell culture is purified and formulated in a pharmaceutically acceptable formulation.
  • Figure 1A Viable cell density
  • Figure IB Viability
  • Figure 1C Titer
  • Figure 3 1.0 start perfusion volume, no temperature shift: solid circle. 1.0 start perfusion volume, temperature shift: open circle (o). 0.75 start perfusion volume perfusion volume, no temperature shift: solid square ( ⁇ ). 0.75 start perfusion volume, temperature shift: open square ( ⁇ ).
  • Figure 4 Batch start with low asparagine amount: open triangle ( ⁇ ). Batch start with control L-asparagine amount: solid triangle (A). Fed-batch start with low L-asparagine amount: open diamond (0). Fed-batch start with control L-asparagine amount: solid diamond ( ⁇ ). Sparge with drilled pipe: Solid line. Sparge with sintered sparger: dashed line.
  • Figure 4A Viable Cell Density, Figure 4B Viability, Figure 4C PCV Adjusted Titer
  • Figure 5 Cultures grown in medium containing 17.3 mM or 5 mM L-asparagine and 4.6 mM or 10 mM L-glutamine. 17.3mM L-asparagine and 4.6 mM L-glutamine solid diamond ( ⁇ ) or 5 mM L-asparagine, 10 mM L-glutamine open diamond (0).
  • Figure 5A Viable cell density.
  • Figure 5B Titer.
  • Figure 5C Packed cell volume (PCV).
  • Figure 5D PCV-adjusted titer.
  • Figure 5E Viability.
  • Figure 6 Cultures at 2L bench scale and 500L pilot scale, with 5 mM L-asparagine, 10 mM L-glutamine.
  • Medium containing 5 mM L-asparagine, 10 mM L-glutamine at 2L bench scale is represented by the solid diamond ( ⁇ ) and the 500L pilot scale is represented by the open diamond (0)
  • Figure 6A Viable cell density.
  • Figure 6B Titer.
  • Figure 6C Packed cell volume (PCV).
  • Figure 6D PCV-adjusted titer.
  • Figure 6E Viability.
  • packed cell volume can be limited to a desired level during the production phase by inducing cell growth-arrest in the cultured cells by exposure to low L-asparagine conditions.
  • Cell growth-arrest can be achieved and maintained by using a perfusion culture medium that contains a limiting concentration of L-asparagine and maintaining a low concentration of L- asparagine in the cell culture (5mM or less).
  • the growth-arrested cells showed increased productivity when growth-arrest was initiated by low L-asparagine or through L-asparagine starvation and the growth-arrested cells were subsequently maintained with the cell culture and perfusion medium having an L-asparagine concentration of 5mM or less.
  • a growth-arrested, high productivity production phase can be achieved by manipulating the concentration of L-asparagine.
  • depletion of L- asparagine resulted in growth-arrest.
  • the culture was repeatedly starved of L-asparagine despite repeated feedings due to consumption of L-asparagine and/or the conversion to L-aspartate.
  • the extracellular L-asparagine can be converted to L-aspartate and ammonia. L-asparagine depletion resulted in cell cycle arrest.
  • the feed medium can be switched from a formulation containing a high (growth promoting) level of L- asparagine during bolus feeds to a lower (growth-arresting) level of L-asparagine during perfusion feeding.
  • Cell cultures that have been growth-arrested by limiting L-asparagine can be stimulated into a high productivity state by adding back low levels of L-asparagine.
  • the method includes inducing cell growth-arrest in a mammalian cell culture by subjecting the cell culture to serum- free medium having an L- asparagine concentration of 5mM or less which includes OmM L-asparageine).
  • Such induction can be initiated by L-asparagine starvation or by creating a low L-asparagine environment by perfusing the culture with a serum-free perfusion medium having an L- asparagine concentration of 5mM or less and maintaining the culture in a low L-asparagine environment.
  • the cell culture is then maintained in the growth-arrested state by perfusing with a serum-free perfusion medium with an L-asparagine at a concentration of 5mM or less and maintaining the culture in the low L-asparagine environment.
  • Mammalian cells maintained in the low asparagine growth-arrested state exhibited greater productivity (g protein/cell/day and g protein/cell mass/day) than those which were not low asparagine growth-arrested.
  • Such method is also useful for limiting a mammalian cell culture at a desired packed cell volume.
  • Packed cell volume during the production phase could be limited at a desired level by reducing L-asparagine levels in the production culture medium.
  • Asparagine concentrations of 5mM or less in the perfusion medium were sufficient to control cell growth during culture and limit to a desired packed cell volume.
  • the methods described herein provide greater control over cell growth to high product titer cell cultures; and as such can simplify the gassing strategy compared to a high biomass perfusion processes and minimize product loss during harvest and downstream processing.
  • the method begins with establishing a mammalian cell culture in a production bioreactor.
  • a production bioreactor Preferably smaller production bioreactors are used, in one embodiment the bioreactors are 500L to 2000L. In a preferred embodiment, 1000L - 2000L bioreactors are used.
  • the seed cell density used to inoculate the bioreactor can have a positive impact on the level of recombinant protein produced.
  • the bioreactor is inoculated with at least 0.5 xlO 6 up to and beyond 3.0 xlO 6 viable cells/mL in a serum-free culture medium. In a preferred embodiment the inoculation is l .OxlO 6 viable cells/mL.
  • the mammalian cells then undergo an exponential growth phase.
  • the cell culture can be maintained without supplemental feeding until a desired cell density is achieved.
  • the cell culture is maintained for up to 3 days without supplemental feeding followed by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less to induce and maintain low L-asparagine growth-arrest.
  • the culture can be inoculated at a desired cell density to begin the production phase without a brief growth phase with cell growth-arrest initiated immediately upon inoculation by perfusing the cell culture with serum-free perfusion medium containing 5mM or less L-asparagine to induce and maintain low L-asparagine growth-arrest.
  • the switch from the growth phase to production phase can also be initiated by L-asparagine starvation (subjecting cells to a 0 mM L-asparagine environment) followed by perfusion with a cell culture medium having an L-asparagine concentration of equal to or less than 5 mM. and maintaining the concentrating of L-asparagine in the cell culture at that level.
  • growth-arrest which may also be referred to as “cell growth- arrest” is the point where cells stop increasing in number or when the cell cycle no longer progresses. Growth-arrest can be monitored by determining the viable cell density of a cell culture. Some cells in a growth-arrested state may increase in size but not number, so the packed cell volume of a growth-arrested culture may increase. Growth-arrest can be reversed to some extent, if the cells are not in declining health, by adding additional L-asparagine to the cell culture.
  • L-asparagine starvation occurs when the L-asparagine concentration in a cell culture medium is effectively at OmM. Starvation can result in growth-arrest within 24 hours. Starvation for longer than 48 hours could damage the health of the cells.
  • the L-asparagine concentration in the cell culture must be maintained at 5mM or less.
  • the cell culture medium concentration of L-asparagine required to arrest cell growth is dependent on the ability of the cells to make their own asparagine. For cultures where cells can make their own asparagine, a lower concentration, or even removal of L-asparagine from the medium may be required for growth-arrest. For cultures that are unable to make their own asparagine, for example, cells that lack active asparagine synthetase enzyme, concentrations above zero up to 5 mM L-asparagine could be used to arrest growth.
  • packed cell volume As used herein, "packed cell volume” (PCV), also referred to as “percent packed cell volume” (%PCV), is the ratio of the volume occupied by the cells, to the total volume of cell culture, expressed as a percentage (see Stettler, wt al., (2006) Biotechnol Bioeng. Dec 20:95(6): 1228-33). Packed cell volume is a function of cell density and cell diameter; increases in packed cell volume could arise from increases in either cell density or cell diameter or both. Packed cell volume is a measure of the solid content in the cell culture. Solids are removed during harvest and downstream purification. More solids mean more effort to separate the solid material from the desired product during harvest and downstream purification steps.
  • the desired product can become trapped in the solids and lost during the harvest process, resulting in a decreased product yield.
  • host cells vary in size and cell cultures also contain dead and dying cells and other cellular debris
  • packed cell volume is a more accurate way to describe the solid content within a cell culture than cell density or viable cell density. For example, a 2000L culture having a cell density of 50 x 10 6 cells/ml would have vastly different packed cell volumes depending on the size of the cells.
  • some cells when in a growth-arrested state, will increase in size, so the packed cell volume prior to growth-arrest and post growth-arrest will likely be different, due to increase in biomass as a result to cell size increase.
  • the percent packed cell volume is equal to or less than 35%.
  • the desired packed cell volume maintained during the production phase is equal to or less than 35%.
  • the packed cell volume is equal to or less than 30%.
  • the packed cell volume is equal to or less than 20%.
  • the packed cell volume is equal to or less than 15%.
  • the packed cell volume is equal to or less than 10%.
  • cell density refers to the number of cells in a given volume of culture medium.
  • “Viable cell density” refers to the number of live cells in a given volume of culture medium, as determined by standard viability assays (such as trypan blue dye exclusion method).
  • the desired viable cell density at the transition between the growth and production phases and maintained during the production phase is one that provides a packed cell volume of equal to or less than 35%.
  • the viable cell density is at least about lOxlO 6 viable cells/mL to 80x10 6 viable cells/mL. In one embodiment the viable cell density is at least about lOxlO 6 viable cells/mL to 70x10 6 viable cells/mL. In one embodiment the viable cell density is at least about lOxlO 6 viable cells/mL to 60x10 6 viable cells/mL. In one embodiment the viable cell density is at least about lOxlO 6 viable cells/mL to 50x10 6 viable cells/mL.
  • the viable cell density is at least about lOxlO 6 viable cells/mL to 40x10 6 viable cells/mL. In a preferred embodiment the viable cell density is at least about lOxlO 6 viable cells/mL to 30xl0 6 viable cells/mL. In another preferred embodiment the viable cell density is at least about lOxlO 6 viable cells/mL to 20x10 6 viable cells/mL. In another preferred embodiment, the viable cell density is at least about 20x10 6 viable cells/mL to 30xl0 6 viable cells/mL. In another preferred embodiment the viable cell density is at least about 20x10 6 viable cells/mL to at least about 25x10 6 viable cells/mL, more preferably at least about 20x10 6 viable cells/mL.
  • Lower packed cell volume during the production phase helps mitigate dissolved oxygen sparging problems that can hinder higher cell density perfusion cultures.
  • the lower packed cell volume also allows for a smaller media volume which allows for the use of smaller media storage vessels and can be combined with slower flow rates.
  • Lower packed cell volume also has less impact on harvest and downstream processing, compared to higher cell biomass cultures. All of which reduces the costs associated with manufacturing recombinant protein therapeutics.
  • Batch culture a discontinuous method where cells are grown in a fixed volume of culture media for a short period of time followed by a full harvest. Cultures grown using the batch method experience an increase in cell density until a maximum cell density is reached, followed by a decline in viable cell density as the media components are consumed and levels of metabolic by-products (such as lactate and ammonia) accumulate. Harvest typically occurs at the point when the maximum cell density is achieved (typically 5-10xl0 6 cells/mL, depending on media formulation, cell line, etc).
  • the batch process is the simplest culture method, however viable cell density is limited by the nutrient availability and once the cells are at maximum density, the culture declines and production decreases. There is no ability to extend a production phase because the accumulation of waste products and nutrient depletion rapidly lead to culture decline, (typically around 3 to 7 days).
  • Fed-batch culture improves on the batch process by providing bolus or continuous media feeds to replenish those media components that have been consumed. Since fed-batch cultures receive additional nutrients throughout the run, they have the potential to achieve higher cell densities (>10 to 30xl0 6 cells/ml, depending on media formulation, cell line, etc)) and increased product titers, when compared to the batch method. Unlike the batch process, a biphasic culture can be created and sustained by manipulating feeding strategies and media formulations to distinguish the period of cell proliferation to achieve a desired cell density (the growth phase) from the period of suspended or slow cell growth (the production phase). As such, fed batch cultures have the potential to achieve higher product titers compared to batch cultures.
  • a batch method is used during the growth phase and a fed-batch method used during the production phase, but a fed-batch feeding strategy can be used throughout the entire process.
  • bioreactor volume is a limiting factor which limits the amount of feed.
  • metabolic by-product accumulation will lead to culture decline, which limits the duration of the production phase, about 1.5 to 3 weeks.
  • Fed-batch cultures are discontinuous and harvest typically occurs when metabolic by-product levels or culture viability reach predetermined levels.
  • Perfusion methods offer potential improvement over the batch and fed-batch methods by adding fresh media and simultaneously removing spent media.
  • Typical large scale commercial cell culture strategies strive to reach high cell densities, 60 - 90(+) x 10 6 cells/mL where almost a third to over one-half of the reactor volume is biomass. With perfusion culture, extreme cell densities of >1 x 10 8 cells/mL have been achieved and even higher densities are predicted.
  • Typical perfusion cultures begin with a batch culture start-up lasting for a day or two followed by continuous, step-wise and/or intermittent addition of fresh feed media to the culture and simultaneous removal of spend media with the retention of cells and additional high molecular weight compounds such as proteins (based on the filter molecular weight cutoff) throughout the growth and production phases of the culture.
  • a large scale cell culture strategy that combines fed batch feeding during the growth phase followed by continuous perfusion during the production phase.
  • the method targets a production phase where the cell culture is maintained at a packed cell volume of less than or equal to 35%.
  • the method also provides the initiation and maintenance of cell growth-arrest due to low asparagine.
  • Fed batch culture is a widely -practiced culture method for large scale production of proteins from mammalian cells. See e.g. Chu and Robinson (2001), Current Opin.
  • a fed batch culture of mammalian cells is one in which the culture is fed, either continuously or periodically, with a concentrated feed medium containing nutrients. Feeding can occur on a predetermined schedule of, for example, every day, once every two days, once every three days, etc. When compared to a batch culture, in which no feeding occurs, a fed batch culture can produce greater amounts of recombinant protein. See e.g. U.S. Patent No. 5,672,502.
  • a fed-batch culture with bolus feeds is used to maintain a cell culture during the growth phase.
  • Perfusion feeding can then be used during a production phase.
  • perfusion begins when the cells have reached a production phase.
  • perfusion begins on or about day 5 to on or about day 9 of the cell culture.
  • perfusion begins on or about day 5 to on or about day 7 of the cell culture.
  • the initiation of cell growth-arrest in the fed-batch culture can be initiated by subjecting the fed-batch culture to a period of L-asparagine starvation followed by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5 mM or less.
  • the L-asparagine concentration of the cell culture medium is monitored prior to and during L-asparagine starvation.
  • the initiation of cell growth-arrest in the fed-batch culture can be achieved by perfusion with a serum free perfusion medium having an L-asparagine concentration of 5 mM or less.
  • Using bolus feeding during the growth phase allows the cells to transition into the production phase, resulting in less dependence on a temperature shift as a means of initiating and controlling the production phase, however a temperature shift of 36°C to 31°C can take place between the growth phase and production phase.
  • the shift is from 36°C to 33°C.
  • the bioreactor can be inoculated with at least 0.5 xlO 6 up to and beyond 3.0 xlO 6 viable cells/mL in a serum-free culture medium, preferably 1.0x106 viable cells/mL.
  • Perfusion culture is one in which the cell culture receives fresh perfusion feed medium while simultaneously removing spent medium.
  • Perfusion can be continuous, stepwise, intermittent, or a combination of any or all of any of these. Perfusion rates can be less than a working volume to many working volumes per day.
  • the cells are retained in the culture and the spent medium that is removed is substantially free of cells or has significantly fewer cells than the culture. Recombinant proteins expressed by the cell culture can also be retained in the culture.
  • Perfusion can be accomplished by a number of means including centrifugation, sedimentation, or filtration, See e.g. Voisard et al., (2003), Biotechnology and Bioengineering 82:751-65.
  • a preferred filtration method is alternating tangential flow filtration. Alternating tangential flow is maintained by pumping medium through hollow-fiber filter modules. See e.g. US Patent No. 6,544,424; Furey (2002) Gen. Eng. News. 22 (7), 62-63.
  • perfusion flow rate is the amount of media that is passed through (added and removed) from a bioreactor, typically expressed as some portion or multiple of the working volume, in a given time.
  • Working volume refers to the amount of bioreactor volume used for cell culture.
  • Perfusion flow rate is one working volume or less per day.
  • Perfusion feed medium can be formulated to maximize perfusion nutrient concentration to minimize perfusion rate.
  • cell culture or “culture” is meant the growth and propagation of cells outside of a multicellular organism or tissue. Suitable culture conditions for mammalian cells are known in the art. See e.g. Animal cell culture: A Practical Approach, D. Rickwood, ed., Oxford University Press, New York (1992). Mammalian cells may be cultured in suspension or while attached to a solid substrate. Fluidized bed bioreactors, hollow fiber bioreactors, roller bottles, shake flasks, or stirred tank bioreactors, with or without microcarriers, can be used. In one embodiment 500L to 2000L bioreactors are used. In a preferred embodiment, 1000L to 2000L bioreactors are used.
  • cell culture medium is a media suitable for growth of animal cells, such as mammalian cells, in in vitro cell culture.
  • Cell culture media formulations are well known in the art.
  • cell culture media are comprised of buffers, salts, carbohydrates, amino acids, vitamins and trace essential elements. "Serum-free” applies to a cell culture medium that does not contain animal sera, such as fetal bovine serum.
  • tissue culture media including defined culture media
  • any one or a combination of the following cell culture media can be used: RPMI- 1640 Medium, RPMI-1641 Medium, Dulbecco's Modified Eagle's Medium (DMEM), Minimum Essential Medium Eagle, F- 12K Medium, Ham's F12 Medium, Iscove's Modified Dulbecco's Medium, McCoy's 5A Medium, Leibovitz's L-15 Medium, and serum- free media such as EX-CELLTM 300 Series (JRH Biosciences, Lenexa, Kansas), among others. Serum-free versions of such culture media are also available.
  • DMEM Dulbecco's Modified Eagle's Medium
  • F- 12K Medium Minimum Essential Medium Eagle
  • Ham's F12 Medium Ham's F12 Medium
  • Iscove's Modified Dulbecco's Medium McCoy's 5A Medium
  • Leibovitz's L-15 Medium and serum- free media
  • serum-free media such as EX
  • Cell culture media may be supplemented with additional or increased concentrations of components such as amino acids, salts, sugars, vitamins, hormones, growth factors, buffers, antibiotics, lipids, trace elements and the like, depending on the requirements of the cells to be cultured and/or the desired cell culture parameters.
  • components such as amino acids, salts, sugars, vitamins, hormones, growth factors, buffers, antibiotics, lipids, trace elements and the like, depending on the requirements of the cells to be cultured and/or the desired cell culture parameters.
  • Concentrated feed medium may be based on just about any cell culture media formulation. Such a concentrated feed medium can contain most of the components of the cell culture medium at, for example, about 5X, 6X, 7X, 8X, 9X, 10X, 12X, 14X, 16X, 20X, 30X, 50X, lOOx, 200X, 400X, 600X, 800X, or even about 1000X of their normal amount. Concentrated feed media are often used in fed batch culture processes.
  • the method according to the present invention may be used to improve the production of recombinant proteins in multiple phase culture processes.
  • cells are cultured in two or more distinct phases.
  • cells may be cultured first in one or more growth phases, under environmental conditions that maximize cell proliferation and viability, then transferred to a production phase, under conditions that maximize protein production.
  • a production phase under conditions that maximize protein production.
  • the growth and production phases may be preceded by, or separated by, one or more transition phases.
  • the method according to the present invention can be employed at least during the growth and production phase of the final production phase of a commercial cell culture, although it may also be employed in a preceding growth phase.
  • a production phase can be conducted at large scale.
  • a large scale process can be conducted in a volume of at least about 100, 500, 1000, 2000, 3000, 5000, 7000, 8000, 10,000, 15,000, 20,000 liters.
  • production is conducted in 500L, 1000L and/or 2000L bioreactors.
  • a growth phase may occur at a higher temperature than a production phase.
  • a growth phase may occur at a first temperature from about 35°C to about 38°C
  • a production phase may occur at a second temperature from about 29°C to about 37°C, optionally from about 30°C to about 36°C or from about 30°C to about 34°C.
  • chemical inducers of protein production such as, for example, caffeine, butyrate, and hexamethylene bisacetamide (HMBA) may be added at the same time as, before, and/or after a temperature shift. If inducers are added after a temperature shift, they can be added from one hour to five days after the temperature shift, optionally from one to two days after the temperature shift. The cell cultures can be maintained for days or even weeks while the cells produce the desired protein(s).
  • Samples from the cell culture can be monitored and evaluated using any of the analytical techniques known in the art. Variety of parameters including recombinant protein and medium quality and characteristics can be monitored for the duration of the culture. Samples can be taken and monitored intermittently at a desirable frequency, including continuous monitoring, real time or near real time. In one embodiment the L-asparagine concentration of the cell culture medium is monitored prior to and during L-asparagine starvation.
  • the cell cultures that precede the final production culture are used to generate the seed cells that will be used to inoculate the production bioreactor, the N- 1 culture.
  • the seed cell density can have a positive impact on the level of recombinant protein produced. Product levels tend to increase with increasing seed density. Improvement in titer is tied not only to higher seed density, but is likely to be influenced by the metabolic and cell cycle state of the cells that are placed into production.
  • Seed cells can be produced by any culture method.
  • a preferred method is a perfusion culture using alternating tangential flow filtration.
  • An N- 1 bioreactor can be run using alternating tangential flow filtration to provide cells at high density to inoculate a production bioreactor.
  • the N- 1 stage may be used to grow cells to densities of >90 x 10 6 cells/mL.
  • the N-1 bioreactor can be used to generate bolus seed cultures or can be used as a rolling seed stock culture that could be maintained to seed multiple production bioreactors at high seed cell density.
  • the duration of the growth stage of production can range from 7 to 14 days and can be designed so as to maintain cells in exponential growth prior to inoculation of the production bioreactor.
  • Perfusion rates, medium formulation and timing are optimized to grow cells and deliver them to the production bioreactor in a state that is most conducive to optimizing their production. Seed cell densities of >15 x 10 6 cells/mL can be achieved for seeding production bioreactors. Higher seed cell densities at inoculation can decrease or even eliminate the time needed to reach a desired production density.
  • the invention finds particular utility in improving cell growth, viability and/or protein production via cell culture processes.
  • the cell lines also referred to as "host cells" used in the invention are genetically engineered to express a polypeptide of commercial or scientific interest.
  • Cell lines are typically derived from a lineage arising from a primary culture that can be maintained in culture for an unlimited time. Genetically engineering the cell line involves transfecting, transforming or transducing the cells with a recombinant polynucleotide molecule, and/or otherwise altering (e.g., by homologous recombination and gene activation or fusion of a recombinant cell with a non-recombinant cell) so as to cause the host cell to express a desired recombinant polypeptide.
  • Animal cell lines are derived from cells whose progenitors were derived from a multicellular animal.
  • One type of animal cell line is a mammalian cell line.
  • a wide variety of mammalian cell lines suitable for growth in culture are available from the American Type Culture Collection (Manassas, Va.) and commercial vendors. Examples of cell lines commonly used in the industry include VERO, BHK, HeLa, CV1 (including Cos), MDCK, 293, 3T3, myeloma cell lines (e.g., NSO, NS 1), PC12, WI38 cells, and Chinese hamster ovary (CHO) cells. CHO cells are widely used for the production of complex recombinant proteins, e.g.
  • cytokines, clotting factors, and antibodies Brasel et al. (1996), Blood 88:2004-2012; Kaufman et al. (1988), J. Biol Chem 263:6352-6362; McKinnon et al. (1991), J Mol Endocrinol 6:231-239; Wood et al. (1990), J. Immunol. 145:3011-3016).
  • DHFR dihydrofolate reductase
  • the methods of the invention can be used to culture cells that express recombinant proteins of interest.
  • the expressed recombinant proteins may be secreted into the culture medium from which they can be recovered and/or collected.
  • the proteins can be purified, or partially purified, from such culture or component (e.g., from culture medium) using known processes and products available from commercial vendors.
  • the purified proteins can then be "formulated", meaning buffer exchanged, sterilized, bulk-packaged, and/or packaged for a final user. Suitable formulations for pharmaceutical compositions include those described in Remington's Pharmaceutical Sciences, 18th ed. 1995, Mack Publishing Company, Easton, PA.
  • peptide As used herein "peptide,” “polypeptide” and “protein” are used interchangeably throughout and refer to a molecule comprising two or more amino acid residues joined to each other by peptide bonds. Peptides, polypeptides and proteins are also inclusive of modifications including, but not limited to, glycosylation, lipid attachment, sulfation, gamma- carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation. Polypeptides can be of scientific or commercial interest, including protein-based drugs. Polypeptides include, among other things, antibodies, fusion proteins, and cytokines.
  • Peptides, polypeptides and proteins are produced by recombinant animal cell lines using cell culture methods and may be referred to as "recombinant peptide", “recombinant polypeptide” and “recombinant protein”.
  • the expressed protein(s) may be produced intracellularly or secreted into the culture medium from which it can be recovered and/or collected.
  • TNF tumor necrosis factor
  • flt3 ligand WO 94/28391
  • erythropoeitin erythropoeitin
  • thrombopoeitin thrombopoeitin
  • calcitonin IL-2
  • angiopoietin-2 angiopoietin-2
  • ligand for receptor activator of NF-kappa B (RANKL, WO 01/36637), tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, WO 97/01633), thymic stroma-derived lymphopoietin, granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor (GM-CSF, Australian Patent No.
  • mast cell growth factor keratinocyte growth factor
  • stem cell growth factor keratinocyte growth factor
  • RANTES human fibrinogen- like 2 protein
  • growth hormone insulin, insulinotropin, insulin- like growth factors, parathyroid hormone, interferons including a-interferons, ⁇ -interferon, and consensus interferons (US Patent Nos.
  • TNFR tumor necrosis factor receptor
  • IL-1 receptor antagonists include: both forms of tumor necrosis factor receptor (TNFR, referred to as p55 and p75, US Patent No. 5,395,760 and US Patent No. 5,610,279), Interleukin- 1 (IL- 1) receptors (types I and II; EP Patent No. 0460846, US Patent No. 4,968,607, and US Patent No. 5,767,064,), IL-1 receptor antagonists (US Patent No.
  • IL- 1 antagonists or inhibitors US Patent Nos. 5,981,713, 6,096,728, and 5,075,222
  • IL-2 receptors IL-4 receptors
  • EP Patent No. 0 367 566 and US Patent No. 5,856,296 IL- 15 receptors
  • IL- 17 receptors IL-18 receptors
  • Fc receptors granulocyte-macrophage colony stimulating factor receptor
  • granulocyte colony stimulating factor receptor receptors for oncostatin-M and leukemia inhibitory factor
  • receptor activator of NF-kappa B RANK, WO 01/36637 and US Patent No. 6,271,349
  • osteoprotegerin US. Patent No. 6,015,938
  • receptors for TRAIL including TRAIL receptors 1, 2, 3, and 4
  • receptors that comprise death domains such as Fas or Apoptosis-Inducing Receptor (AIR).
  • CD proteins proteins comprising all or part of the amino acid sequences of differentiation antigens (referred to as CD proteins) or their ligands or proteins substantially similar to either of these.
  • CD proteins are disclosed in Leukocyte Typing VI (Proceedings of the Vlth International Workshop and Conference, Kishimoto, Kikutani et al., eds., Kobe, Japan, 1996). Similar CD proteins are disclosed in subsequent workshops. Examples of such antigens include CD22, CD27, CD30, CD39, CD40, and ligands thereto (CD27 ligand, CD30 ligand, etc.).
  • CD antigens are members of the TNF receptor family, which also includes 4 IBB and OX40.
  • the ligands are often members of the TNF family, as are 4 IBB ligand and OX40 ligand.
  • Enzymatically active proteins or their ligands can also be produced using the invention.
  • proteins comprising all or part of one of the following proteins or their ligands or a protein substantially similar to one of these: a disintegrin and metalloproteinase domain family members including TNF-alpha Converting Enzyme, various kinases, glucocerebrosidase, superoxide dismutase, tissue plasminogen activator, Factor VIII, Factor IX, apolipoprotein E, apolipoprotein A-I, globins, an IL-2 antagonist, alpha- 1 antitrypsin, ligands for any of the above-mentioned enzymes, and numerous other enzymes and their ligands.
  • a disintegrin and metalloproteinase domain family members including TNF-alpha Converting Enzyme, various kinases, glucocerebrosidase, superoxide dismutase, tissue plasminogen activ
  • antibody includes reference to both glycosylated and non-glycosylated immunoglobulins of any isotype or subclass or to an antigen-binding region thereof that competes with the intact antibody for specific binding, unless otherwise specified, including human, humanized, chimeric, multi-specific, monoclonal, polyclonal, and oligomers or antigen binding fragments thereof.
  • proteins having an antigen binding fragment or region such as Fab, Fab', F(ab')2, Fv, diabodies, Fd, dAb, maxibodies, single chain antibody molecules, complementarity determining region (CDR) fragments, scFv, diabodies, triabodies, tetrabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to a target polypeptide.
  • antibody is inclusive of, but not limited to, those that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from a host cell transfected to express the antibody.
  • antibodies include, but are not limited to, those that recognize any one or a combination of proteins including, but not limited to, the above-mentioned proteins and/or the following antigens: CD2, CD3, CD4, CD8, CDl la, CD14, CD18, CD20, CD22, CD23, CD25, CD33, CD40, CD44, CD52, CD80 (B7.1), CD86 (B7.2), CD 147, IL-la, IL- ⁇ , IL-2, IL-3, IL-7, IL-4, IL-5, IL-8, IL-10, IL-2 receptor, IL-4 receptor, IL-6 receptor, IL-13 receptor, IL- 18 receptor subunits, FGL2, PDGF- ⁇ and analogs thereof (see US Patent Nos.
  • VEGF vascular endothelial growth factor
  • TGF TGF- 2
  • TGF- ⁇ TGF- ⁇
  • EGF receptor see US Patent No. 6,235,883
  • VEGF receptor hepatocyte growth factor
  • osteoprotegerin ligand interferon gamma
  • B lymphocyte stimulator BlyS, also known as BAFF, THANK, TALL- 1, and zTNF4; see Do and Chen-Kiang (2002), Cytokine Growth Factor Rev.
  • the invention can also be used to produce recombinant fusion proteins comprising, for example, any of the above-mentioned proteins.
  • recombinant fusion proteins comprising one of the above-mentioned proteins plus a multimerization domain, such as a leucine zipper, a coiled coil, an Fc portion of an immunoglobulin, or a substantially similar protein, can be produced using the methods of the invention. See e.g. WO94/10308; Lovejoy et al. (1993), Science 259: 1288-1293; Harbury et al. (1993), Science 262: 1401-05; Harbury et al.
  • fusion proteins proteins in which a portion of a receptor is fused to an Fc portion of an antibody such as etanercept (a p75 TNFR:Fc), and belatacept (CTLA4:Fc).
  • CHO cells expressing a recombinant antibody were inoculated into 2L production bioreactors at lxlO 6 viable cells/mL in a working volume of 1500 ml of a serum- free defined medium for the fed-batch start and 1800mL for the batch start. Cultures were maintained at 36°C, dissolved oxygen (DO) at 30%, agitation at 215 RPM. Glucose was maintained above 0 g/L and below 8 g/L.
  • Perfusion (0.75 Vol/day) for the fed-batch cultures. Perfusion was accomplished using an alternating tangential flow perfusion and filtration system (Refine Technologies, Hanover, NJ, 50 kDa hollow fiber filter). Prior to starting perfusion the fed-batch cultures received bolus feeds of a concentrated serum-free defined feed media on day 4 (7.5% of initial working volume) and day 6 (10% initial working volume). Perfusion rates are provided in Table 1.
  • Viable cell density (VCD) and viability were determined using Vi-Cell (Beckman Coulter, Brea, CA). Titer was measured by HPLC analysis. Packed cell volume was determined using VoluPAC (Sartorius, Goettingen, Germany).
  • a temperature shift (36.0°C to 33.0°C) was applied when the viable cell density exceeded 20 x 10 6 viable cells/mL which was day 7 and day 11 for the batch and fed-batch start conditions respectively.
  • the viable cell density for the fed batch was between 27.7 and 30.7 x 10 6 viable cells/mL while VCD of the batch culture was between 22.5 and 27.4 x 10 6 viable cells/mL (Figure 1A).
  • Viability of the fed batch culture was between 73.9 and 77.5% while the batch culture viability was between 72.5 and 83.1% ( Figure IB).
  • the titer of the fed batch culture was between 15.3 and 16.1 g/L while the batch culture titer was between 10.6 and 12.3 g/L ( Figure 1C).
  • variable cell density (IVCD) values were similar for all four cultures by day 15 (approximately 230 x 10 6 cell days/mL), the specific productivity was higher in the fed-batch start-up conditions.
  • the fed batch cultures were continued to day 24.
  • a titer of 20 g/L was achieved at 20 days.
  • CHO cells expressing a recombinant antibody were inoculated into 2L production bioreactors at lxlO 6 viable cells/mL in a working volume of 1500 ml of a serum- free defined medium for the batch start and 1300mL for the fed-batch start. Cultures were maintained at 36°C, DO at 30%, agitation at 215 RPM for batch cultures. The fed-batch culture was agitated at 430RPM. Fed-batch culture was fed to 7 g/L glucose daily prior to perfusion and all cultures were maintained at or above 4 g/L glucose during perfusion.
  • Perfusion (alternating tangential flow) was started on day 4 (0.25 Vol/day) for the batch cultures and on day 8 (0.75 Vol/day) for the fed-batch culture. Prior to starting perfusion the fed-batch culture received bolus feeds of a concentrated serum-free defined feed media on day 4 (7.5% of initial working volume) and day 6 (10% initial working volume). Perfusion flow rates settings are provided in Table 2. The cultures were maintained for 21 days.
  • a temperature shift (36.0°C to 33.0°C) was applied to the batch cultures on day 6 when the viable cell density exceeded 20 x 10 6 viable cells/mL, as in Example 1.
  • the fed batch culture was maintained at 36.0°C for the duration of the culture.
  • the batch start-up method cultures had results similar to those described above with the cells reaching approximately 20 to 25 x 10 6 viable cells/mL with no growth after day 10.
  • the fed-batch culture reached almost 30 x 10 6 viable cells/mL on day 20 after spending most of the culture duration below 20 x 10 6 viable cells/mL, see Figure 2A.
  • the viabilities all remained above 80% until day 10 and then dropping to about 40% by day 20 for the batch start cultures and 60% for the fed-batch culture, see Figure 2B.
  • the titer peaked at almost 15 g/L for the batch start cultures, but it reached over 20 g/L for the high agitation fed-batch culture, see Figure 2C.
  • the fed-batch start-up with high agitation perfusion culture achieved the highest titer (over 20 g/L) in 20 days, more than 5 g/L higher than the batch start-up cultures, which was similar to the results described above. No negative effects of a higher agitation rate were observed. Maintaining a constant temperature did not appear to negatively impact the fed batch culture.
  • CHO cells expressing a recombinant antibody were inoculated into 2L production bioreactors at lxlO 6 cells/mL in a working volume of 1200 ml of a serum- free defined medium. Cultures were maintained at 36°C, DO at 30%. Prior to perfusion, glucose was fed to 7 g/L daily and during perfusion glucose was maintained above 1 g/L. The culture was maintained for 20 days.
  • Temperature shift and perfusion rate did not impact viable cell density, see Figure 3A. However, a temperature shift appears to help preserve viability at later time points in a culture. There appears to be a break out between the temperatures shift conditions starting on Day 15 onward. The viability of the temperature shifted cultures dropped more slowly than the cultures that remained at 36°C, see Figure 3B. As for titer, three cultures showed very similar titers on Day 15 (17.1-17.9 g/L) as well as on Day 20 (22-24 g/L), but one culture had a higher titer on Day 15 (21.58 g/L) as well as on Day 20 (28.33 g/L) (see Figure 3C). Neither the temperature nor perfusion rates appeared to have any impact on titer production, suggesting that cultures can be maintained with different perfusion rates.
  • This experiment was designed to investigate the effects of perfusion medium asparagine concentrations and perfusion start conditions with either L-asparagine limited or non-limited culture environments on viable cell density during the production phase.
  • CHO cells expressing a recombinant antibody were inoculated into 2L production bioreactors at lxl 0 6 cells/mL in a working volume of 1500 ml for both the batch and fed-batch start methods. Cultures were maintained at 36°C, dissolved oxygen (DO) at 30%, agitation at 400 RPM. Sparging was done using either a drilled pipe or a sintered sparger. Glucose was maintained above 0 g/L and below 8 g/L.
  • Perfusion (alternating tangential flow) was started on day 3 (0.29 Vol/day) for the batch start "non-asparagine-limited cultures" and on day 7 (0.48 Vol/day) for the fed-batch "asparagine-limited cultures".
  • the batch culture medium contained lOmM L-asparagine.
  • Prior to starting perfusion the fed-batch cultures received bolus feeds of a concentrated serum-free defined feed media on days 3 and 6 (7% initial working volume) containing 1 13.4mM L-asparagine.
  • Perfusion medium asparagine concentrations were either at a control concentration (17.3mM Asn in a serum free defined perfusion medium) or a low concentration (5mM Asn in a serum free defined perfusion medium). Perfusion was carried out as described above. Perfusion rates are provided in Table 4.
  • Viable cell density (VCD) and viability were determined using Vi-Cell (Beckman Coulter, Brea, CA). Titer was measured by HPLC analysis. All cultures were maintained at 36.0°C.
  • the packed cell volume adjusted titer of the low asparagine fed-batch culture was 17.0 g/L (adjusted for packed cell volume) while the batch culture titer was between 15.4 g/L ( Figure 4C).
  • the controls had titers of 10.2 to 12.9 g/L (batch start) and 14.2 to 15.9 g/L (fed-batch start).
  • This experiment compares media conditions during perfusion.
  • cells were inoculated into a chemically defined batch medium at a working volume of 1.5L, cultured for 3 days and then perfused for 12 days using a chemically defined perfusion medium containing either 17.3 mM L-asparagine and 4.6 mM L-glutamine or 5 mM L-asparagine and 10 mM L-glutamine.
  • Perfusion was accomplished using an alternating tangential flow perfusion and filtration system (Refine Technologies, Hanover, NJ) with a 30 kDa hollow fiber filter (GE Healthcare, Little Chalfont, UK). Perfusion was started on day 3 at a rate of 0.3 culture volumes per day. The rate of perfusion was increased on days 4, 9, and 1 1 as indicated in Table 6 below. Cultures were maintained at 36°C, DO at 30%, pH at 7.0, and agitation at 400 rpm.
  • VFD Vi-Cell
  • Vi-Cell Beckman Coulter, Brea, CA
  • Titer was measured by HPLC analysis.
  • Packed cell volume was determined using VoluPAC (Sartorius, Goettingen, Germany).
  • This example compares the performance of a clonal, antibody-expressing CHO cell line cultured in an ATF perfusion process using asparagine limitation to control growth at bench and pilot scales.
  • the bench-scale model utilized 2L bioreactors and the pilot scale was 500L.
  • cells were inoculated into a chemically defined batch medium at a working volume of 1.5L and at pilot scale the working volume was about 378L.
  • Cells were cultured for 3 days in the batch medium and then perfused for 12 days using a chemically defined perfusion medium containing 5 mM L-asparagine and 10 mM L-glutamine.
  • Perfusion was accomplished using an alternating tangential flow perfusion and filtration system (Refine Technologies, Hanover, NJ) with a 30 kDa hollow fiber filter (GE Healthcare, Little Chalfont, UK). Perfusion was started on day 3 at a rate of 0.3 culture volumes per day. The rate of perfusion was increased on days 4, 9, and 1 1 as indicated in Table 7 below. Cultures were maintained at 36°C, 30% DO, and pH 6.9.
  • Viable cell density (VCD) and viability were determined bench scale using Vi-Cell (Beckman Coulter, Brea, CA) and at pilot scale using a CEDEX (Roche Applied Science, Indianapolis, IN). Titer was measured by HPLC analysis. Packed cell volume was determined using VoluPAC (Sartorius, Goettingen, Germany). Table 6. Perfusion rate schedule

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.

Description

MAMMALIAN CELL CULTURE
FIELD OF INVENTION
The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.
BACKGROUND OF INVENTION
As the demand for greater and greater quantities of therapeutic recombinant proteins increases, positive increases in cell growth, viability and protein production are sought by implementing new methods to improve cell development, media optimization and process control parameters. Much effort is now being placed on process optimization, particularly methods and strategies for growing, feeding, and maintaining production cell cultures.
New cell culture methods that provide even incremental improvements in recombinant protein production are valuable, given the expense of large scale cell culture processes and the growing demand for greater quantities of and lower costs for biological products.
Improvements to cell culture processes, recombinant polypeptide expression, titer, and cell viability that can lead to higher production levels, thereby reducing the costs associated with manufacturing protein therapeutics are needed. The invention fulfills these needs by providing a simple, easy and inexpensive method of controlling cell growth while increasing protein production.
SUMMARY OF THE INVENTION
The present invention provides a method of arresting cell growth in a mammalian cell culture expressing a recombinant protein comprising establishing a mammalian cell culture in a serum-free culture medium in a bioreactor; inducing cell growth-arrest by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less; maintaining the mammalian cells in a growth-arrested state by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less.
The present invention also provides a method of increasing recombinant protein production in a mammalian cell culture expressing a recombinant protein comprising establishing a mammalian cell culture in a serum-free culture medium in a bioreactor; inducing cell growth-arrest by perfusion with a serum-free perfusion medium having an L- asparagine concentration of 5mM or less; maintaining the mammalian cells in a growth- arrested state by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less. In a related embodiment recombinant protein production in the mammalian cell culture is increased compared to a culture where the cells are not subjected to L-asparagine-induced cell growth-arrest. The present invention also provides a method of limiting a mammalian cell culture expressing a recombinant protein at a desired packed cell volume comprising establishing a mammalian cell culture in a serum- free culture medium in a bioreactor; inducing cell growth- arrest by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less; maintaining the mammalian cells in a growth-arrested state by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less.
In one embodiment of the present invention, in any of the methods above the perfusion with a serum- free perfusion medium having an L-asparagine concentration of 5mM or less begins on or before day 3 of the culture. In another embodiment, in any of the methods above induction of cell growth-arrest takes place prior to a production phase. In another embodiment, in any of the methods above induction of cell growth-arrest takes place during a production phase. In another embodiment, in any of the methods above cell growth- arrest is induced by L-asparagine starvation. In yet another embodiment, any of the methods above further comprise a temperature shift from 36°C to 31°C. In another embodiment, any of the methods above further comprise a temperature shift from 36°C to 33°C. In a related embodiment the temperature shift occurs at the transition between a growth phase and a production phase. In yet another embodiment the temperature shift occurs during a production phase. In another embodiment the methods above further comprise a packed cell volume during a production phase less than or equal to 35%. In a related embodiment the packed cell volume during a production phase is less than or equal to 35%
The present invention also provides a method of culturing mammalian cells expressing a recombinant protein comprising; establishing a mammalian cell culture in a serum-free culture medium in a bioreactor; growing the mammalian cells during a growth phase and supplementing the culture medium with bolus feeds of a serum-free feed medium, and maintaining the mammalian cells during a production phase by perfusion with a serum- free perfusion medium, wherein the packed cell volume during the production phase is less than or equal to 35%. In one embodiment of the present invention, perfusion begins on or about day 5 to on or about day 9 of the cell culture. In a related embodiment perfusion begins on or about day 5 to on or about day 7 of the cell culture. In one embodiment perfusion begins when the cells have reached a production phase. In another embodiment the method further comprises inducing cell growth-arrest by L-asparagine starvation followed by perfusion with a serum- free perfusion medium having an L-asparagine concentration of 5 mM or less. In yet another embodiment the method further comprises inducing cell growth-arrest by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5 mM or less. In one embodiment of the invention the concentration of L-asparagine in the serum- free perfusion medium is less than or equal to 5mM. In another embodiment the concentration of L-asparagine in the serum-free perfusion medium is less than or equal to 4.0 mM. In another embodiment the concentration of L-asparagine in the serum- free perfusion medium is less than or equal to 3.0 mM. In still another embodiment the concentration of L- asparagine in the serum-free perfusion medium is less than or equal to 2.0 mM. In yet another embodiment the concentration of L-asparagine in the serum-free perfusion medium is less than or equal to 1.0 mM. In yet another embodiment the concentration of L-asparagine in the serum-free perfusion medium is 0 mM. In another embodiment perfusion is performed at a rate that increases during the production phase from 0.25 working volume per day to 1.0 working volume per day during the cell culture. In a related embodiment perfusion is performed at a rate that reaches 1.0 working volume per day on day 9 to day 11 of the cell culture. In another related embodiment perfusion is performed at a rate that reaches 1.0 working volume per day on day 10 of the cell culture. In yet another embodiment the bolus feeds of serum- free feed medium begin on day 3 or day 4 of the cell culture. In another embodiment of the invention the method further comprises a temperature shift from 36°C to 31°C. In another embodiment the method further comprises a temperature shift from 36°C to 33°C. In a related embodiment the temperature shift occurs at the transition between the growth phase and production phase. In a related embodiment the temperature shift occurs during the production phase.
In one embodiment of the invention the L-asparagine concentration of the cell culture medium is monitored prior to and during L-asparagine starvation.
In one embodiment of the invention the packed cell volume is less than or equal to 35%. In a related embodiment the packed cell volume is less than or equal to 30%.
In one embodiment of the invention the viable cell density of the mammalian cell culture at a packed cell volume less than or equal to 35 % is lOxlO6 viable cells/ml to 80xl06 viable cells/ml. In a related embodiment the viable cell density of the mammalian cell culture is 20x106 viable cells/ml to 30xl06 viable cells/ml.
In one embodiment of the invention perfusion comprises continuous perfusion.
In one embodiment of the invention the rate of perfusion is constant.
In one embodiment of the invention perfusion is performed at a rate of less than or equal to 1.0 working volumes per day.
In another embodiment of the invention the mammalian cell culture is established by inoculating the bioreactor with at least 0.5 x 106 to 3.0 x 106 cells/mL in a serum-free culture medium. In a related embodiment the mammalian cell culture is established by inoculating the bioreactor with at least 0.5 x 106 to 1.5 x 106 cells/mL in a serum- free culture medium. In another embodiment of the invention the perfusion is accomplished by alternating tangential flow.
In another embodiment of the invention the bioreactor has a capacity of at least 500L. In a related embodiment the bioreactor has a capacity of at least 500L to 2000L. In yet another related embodiment the bioreactor has a capacity of at least 1000L to 2000L.
In another embodiment of the invention the mammalian cells are Chinese Hamster
Ovary (CHO)
cells.
In another embodiment of the invention the recombinant protein is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a recombinant fusion protein, or a cytokine.
In another embodiment of the invention any of the methods above further comprise a step of harvesting the recombinant protein produced by the cell culture.
In another embodiment of the invention the recombinant protein produced by the cell culture is purified and formulated in a pharmaceutically acceptable formulation.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 Fed-batch start: solid square (■) and solid circle (·) Batch start: open square (□) and open circle (o).
Figure 1A: Viable cell density, Figure IB: Viability, Figure 1C: Titer
Figure 2 Batch start: open circle (o), Fed-batch start with high agitation: open square (□)
Figure 2A Viable cell density, Figure 2B Viability, Figure 2C Titer, Figure 2D Asparagine concentration
Figure 3 1.0 start perfusion volume, no temperature shift: solid circle. 1.0 start perfusion volume, temperature shift: open circle (o). 0.75 start perfusion volume perfusion volume, no temperature shift: solid square (■). 0.75 start perfusion volume, temperature shift: open square (□).
Figure 3A Viable Cell Density, Figure 3B Viability, Figure 3C Titer
Figure 4 Batch start with low asparagine amount: open triangle (Δ). Batch start with control L-asparagine amount: solid triangle (A). Fed-batch start with low L-asparagine amount: open diamond (0). Fed-batch start with control L-asparagine amount: solid diamond (♦). Sparge with drilled pipe: Solid line. Sparge with sintered sparger: dashed line. Figure 4A Viable Cell Density, Figure 4B Viability, Figure 4C PCV Adjusted Titer
Figure 5 Cultures grown in medium containing 17.3 mM or 5 mM L-asparagine and 4.6 mM or 10 mM L-glutamine. 17.3mM L-asparagine and 4.6 mM L-glutamine solid diamond (♦) or 5 mM L-asparagine, 10 mM L-glutamine open diamond (0).
Figure 5A Viable cell density. Figure 5B Titer. Figure 5C Packed cell volume (PCV). Figure 5D PCV-adjusted titer. Figure 5E Viability.
Figure 6. Cultures at 2L bench scale and 500L pilot scale, with 5 mM L-asparagine, 10 mM L-glutamine. Medium containing 5 mM L-asparagine, 10 mM L-glutamine at 2L bench scale is represented by the solid diamond (♦) and the 500L pilot scale is represented by the open diamond (0)
Figure 6A Viable cell density. Figure 6B Titer. Figure 6C Packed cell volume (PCV). Figure 6D PCV-adjusted titer. Figure 6E Viability.
DETAILED DESCRIPTION OF THE INVENTION
During recombinant protein production it is desirable to have a controlled system where cells are grown to a desired density and then the physiological state of the cells is switched to a growth-arrested, high productivity state where the cells use energy and substrates to produce the recombinant protein of interest instead of making more cells. Methods for accomplishing this goal, such as temperature shifts and small molecule inducers, are not always successful and can have undesirable effects on product quality. As described herein, packed cell volume can be limited to a desired level during the production phase by inducing cell growth-arrest in the cultured cells by exposure to low L-asparagine conditions. Cell growth-arrest can be achieved and maintained by using a perfusion culture medium that contains a limiting concentration of L-asparagine and maintaining a low concentration of L- asparagine in the cell culture (5mM or less).
It was also found that the growth-arrested cells showed increased productivity when growth-arrest was initiated by low L-asparagine or through L-asparagine starvation and the growth-arrested cells were subsequently maintained with the cell culture and perfusion medium having an L-asparagine concentration of 5mM or less.
A growth-arrested, high productivity production phase can be achieved by manipulating the concentration of L-asparagine. As described herein, depletion of L- asparagine resulted in growth-arrest. In a fed-batch culture, once the cell density was sufficiently high (for example >20xl06 viable cells/mL), the culture was repeatedly starved of L-asparagine despite repeated feedings due to consumption of L-asparagine and/or the conversion to L-aspartate. In a cell culture, the extracellular L-asparagine can be converted to L-aspartate and ammonia. L-asparagine depletion resulted in cell cycle arrest. During fed- batch, periods when L-asparagine is present in the culture result in increased productivity and periods when L-asparagine has been depleted result in decreased productivity. In the perfused system, L-asparagine is constantly supplied, total depletion is therefor avoided, and higher concentrations of L-asparagine can be sustained, thus allowing cells to continue multiplying and not be exposed to and environment with depleted or limited L-asparagine. Controlling the concentration of L-asparagine at a sufficiently low concentration (such as concentrations 5mM or less) can keep the cells in a high productivity state while maintaining viability and limiting growth. In a system having bolus and perfusion feeding, the feed medium can be switched from a formulation containing a high (growth promoting) level of L- asparagine during bolus feeds to a lower (growth-arresting) level of L-asparagine during perfusion feeding. Cell cultures that have been growth-arrested by limiting L-asparagine can be stimulated into a high productivity state by adding back low levels of L-asparagine.
For commercial scale cell culture and the manufacture of biological therapeutics, the ability to arrest cell growth and being able to maintain the cells in a growth-arrested state during the production phase would be very desirable. Having cells that were also induced to increase productivity while in the growth-arrested state and being able to maintain this increased productivity, is ideal for manufacturing purposes.
Provided herein is a method of arresting cell growth in a mammalian cell culture expressing a recombinant protein. The method includes inducing cell growth-arrest in a mammalian cell culture by subjecting the cell culture to serum- free medium having an L- asparagine concentration of 5mM or less which includes OmM L-asparageine). Such induction can be initiated by L-asparagine starvation or by creating a low L-asparagine environment by perfusing the culture with a serum-free perfusion medium having an L- asparagine concentration of 5mM or less and maintaining the culture in a low L-asparagine environment. The cell culture is then maintained in the growth-arrested state by perfusing with a serum-free perfusion medium with an L-asparagine at a concentration of 5mM or less and maintaining the culture in the low L-asparagine environment.
Also provided is a method for increasing recombinant protein production in a mammalian cell culture expressing a recombinant protein by inducing a low asparagine cell growth-arrest in a mammalian cell culture. Mammalian cells maintained in the low asparagine growth-arrested state exhibited greater productivity (g protein/cell/day and g protein/cell mass/day) than those which were not low asparagine growth-arrested.
Such method is also useful for limiting a mammalian cell culture at a desired packed cell volume. Packed cell volume during the production phase could be limited at a desired level by reducing L-asparagine levels in the production culture medium. Asparagine concentrations of 5mM or less in the perfusion medium were sufficient to control cell growth during culture and limit to a desired packed cell volume.
The methods described herein provide greater control over cell growth to high product titer cell cultures; and as such can simplify the gassing strategy compared to a high biomass perfusion processes and minimize product loss during harvest and downstream processing.
The method begins with establishing a mammalian cell culture in a production bioreactor. Preferably smaller production bioreactors are used, in one embodiment the bioreactors are 500L to 2000L. In a preferred embodiment, 1000L - 2000L bioreactors are used. The seed cell density used to inoculate the bioreactor can have a positive impact on the level of recombinant protein produced. In one embodiment the bioreactor is inoculated with at least 0.5 xlO6 up to and beyond 3.0 xlO6 viable cells/mL in a serum-free culture medium. In a preferred embodiment the inoculation is l .OxlO6 viable cells/mL.
The mammalian cells then undergo an exponential growth phase. The cell culture can be maintained without supplemental feeding until a desired cell density is achieved. In one embodiment the cell culture is maintained for up to 3 days without supplemental feeding followed by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less to induce and maintain low L-asparagine growth-arrest. In another embodiment the culture can be inoculated at a desired cell density to begin the production phase without a brief growth phase with cell growth-arrest initiated immediately upon inoculation by perfusing the cell culture with serum-free perfusion medium containing 5mM or less L-asparagine to induce and maintain low L-asparagine growth-arrest. In any of the embodiments herein the switch from the growth phase to production phase can also be initiated by L-asparagine starvation (subjecting cells to a 0 mM L-asparagine environment) followed by perfusion with a cell culture medium having an L-asparagine concentration of equal to or less than 5 mM. and maintaining the concentrating of L-asparagine in the cell culture at that level.
Without regard as to how low L-asparagine growth-arrest is induced, higher productivity is seen in the growth-arrested cells that are maintained by perfusing with a low L-asparagine medium and maintaining the cell culture at an L-asparagine level of 5mM or less.
As used herein, "growth-arrest", which may also be referred to as "cell growth- arrest", is the point where cells stop increasing in number or when the cell cycle no longer progresses. Growth-arrest can be monitored by determining the viable cell density of a cell culture. Some cells in a growth-arrested state may increase in size but not number, so the packed cell volume of a growth-arrested culture may increase. Growth-arrest can be reversed to some extent, if the cells are not in declining health, by adding additional L-asparagine to the cell culture.
Growth-arrest is initiated by L-asparagine when the cell density of the culture reaches a level where the concentration of L-asparagine in the culture becomes limiting for continued growth or when the culture is starved of L-asparagine. L-asparagine starvation occurs when the L-asparagine concentration in a cell culture medium is effectively at OmM. Starvation can result in growth-arrest within 24 hours. Starvation for longer than 48 hours could damage the health of the cells. To maintain cells in the growth-arrested state, the L-asparagine concentration in the cell culture must be maintained at 5mM or less. The cell culture medium concentration of L-asparagine required to arrest cell growth is dependent on the ability of the cells to make their own asparagine. For cultures where cells can make their own asparagine, a lower concentration, or even removal of L-asparagine from the medium may be required for growth-arrest. For cultures that are unable to make their own asparagine, for example, cells that lack active asparagine synthetase enzyme, concentrations above zero up to 5 mM L-asparagine could be used to arrest growth.
As used herein, "packed cell volume" (PCV), also referred to as "percent packed cell volume" (%PCV), is the ratio of the volume occupied by the cells, to the total volume of cell culture, expressed as a percentage (see Stettler, wt al., (2006) Biotechnol Bioeng. Dec 20:95(6): 1228-33). Packed cell volume is a function of cell density and cell diameter; increases in packed cell volume could arise from increases in either cell density or cell diameter or both. Packed cell volume is a measure of the solid content in the cell culture. Solids are removed during harvest and downstream purification. More solids mean more effort to separate the solid material from the desired product during harvest and downstream purification steps. Also, the desired product can become trapped in the solids and lost during the harvest process, resulting in a decreased product yield. Since host cells vary in size and cell cultures also contain dead and dying cells and other cellular debris, packed cell volume is a more accurate way to describe the solid content within a cell culture than cell density or viable cell density. For example, a 2000L culture having a cell density of 50 x 106 cells/ml would have vastly different packed cell volumes depending on the size of the cells. In addition, some cells, when in a growth-arrested state, will increase in size, so the packed cell volume prior to growth-arrest and post growth-arrest will likely be different, due to increase in biomass as a result to cell size increase.
At the transition between the growth phase and the production phase, and during the production phase, the percent packed cell volume (%PCV) is equal to or less than 35%. The desired packed cell volume maintained during the production phase is equal to or less than 35%. In a preferred embodiment the packed cell volume is equal to or less than 30%. In another preferred embodiment the packed cell volume is equal to or less than 20%. In another preferred embodiment the packed cell volume is equal to or less than 15%. In yet another preferred embodiment the packed cell volume is equal to or less than 10%.
As used herein, "cell density" refers to the number of cells in a given volume of culture medium. "Viable cell density" refers to the number of live cells in a given volume of culture medium, as determined by standard viability assays (such as trypan blue dye exclusion method).
The desired viable cell density at the transition between the growth and production phases and maintained during the production phase is one that provides a packed cell volume of equal to or less than 35%. In one embodiment, the viable cell density is at least about lOxlO6 viable cells/mL to 80x106 viable cells/mL. In one embodiment the viable cell density is at least about lOxlO6 viable cells/mL to 70x106 viable cells/mL. In one embodiment the viable cell density is at least about lOxlO6 viable cells/mL to 60x106 viable cells/mL. In one embodiment the viable cell density is at least about lOxlO6 viable cells/mL to 50x106 viable cells/mL. In one embodiment the viable cell density is at least about lOxlO6 viable cells/mL to 40x106 viable cells/mL. In a preferred embodiment the viable cell density is at least about lOxlO6 viable cells/mL to 30xl06 viable cells/mL. In another preferred embodiment the viable cell density is at least about lOxlO6 viable cells/mL to 20x106 viable cells/mL. In another preferred embodiment, the viable cell density is at least about 20x106 viable cells/mL to 30xl06 viable cells/mL. In another preferred embodiment the viable cell density is at least about 20x106 viable cells/mL to at least about 25x106 viable cells/mL, more preferably at least about 20x106 viable cells/mL.
Lower packed cell volume during the production phase helps mitigate dissolved oxygen sparging problems that can hinder higher cell density perfusion cultures. The lower packed cell volume also allows for a smaller media volume which allows for the use of smaller media storage vessels and can be combined with slower flow rates. Lower packed cell volume also has less impact on harvest and downstream processing, compared to higher cell biomass cultures. All of which reduces the costs associated with manufacturing recombinant protein therapeutics.
Three methods are typically used in commercial processes for the production of recombinant proteins by mammalian cell culture: batch culture, fed-batch culture, and perfusion culture. Batch culture, a discontinuous method where cells are grown in a fixed volume of culture media for a short period of time followed by a full harvest. Cultures grown using the batch method experience an increase in cell density until a maximum cell density is reached, followed by a decline in viable cell density as the media components are consumed and levels of metabolic by-products (such as lactate and ammonia) accumulate. Harvest typically occurs at the point when the maximum cell density is achieved (typically 5-10xl06 cells/mL, depending on media formulation, cell line, etc). The batch process is the simplest culture method, however viable cell density is limited by the nutrient availability and once the cells are at maximum density, the culture declines and production decreases. There is no ability to extend a production phase because the accumulation of waste products and nutrient depletion rapidly lead to culture decline, (typically around 3 to 7 days).
Fed-batch culture improves on the batch process by providing bolus or continuous media feeds to replenish those media components that have been consumed. Since fed-batch cultures receive additional nutrients throughout the run, they have the potential to achieve higher cell densities (>10 to 30xl06 cells/ml, depending on media formulation, cell line, etc)) and increased product titers, when compared to the batch method. Unlike the batch process, a biphasic culture can be created and sustained by manipulating feeding strategies and media formulations to distinguish the period of cell proliferation to achieve a desired cell density (the growth phase) from the period of suspended or slow cell growth (the production phase). As such, fed batch cultures have the potential to achieve higher product titers compared to batch cultures. Typically a batch method is used during the growth phase and a fed-batch method used during the production phase, but a fed-batch feeding strategy can be used throughout the entire process. However, unlike the batch process, bioreactor volume is a limiting factor which limits the amount of feed. Also, as with the batch method, metabolic by-product accumulation will lead to culture decline, which limits the duration of the production phase, about 1.5 to 3 weeks. Fed-batch cultures are discontinuous and harvest typically occurs when metabolic by-product levels or culture viability reach predetermined levels.
Perfusion methods offer potential improvement over the batch and fed-batch methods by adding fresh media and simultaneously removing spent media. Typical large scale commercial cell culture strategies strive to reach high cell densities, 60 - 90(+) x 106 cells/mL where almost a third to over one-half of the reactor volume is biomass. With perfusion culture, extreme cell densities of >1 x 108 cells/mL have been achieved and even higher densities are predicted. Typical perfusion cultures begin with a batch culture start-up lasting for a day or two followed by continuous, step-wise and/or intermittent addition of fresh feed media to the culture and simultaneous removal of spend media with the retention of cells and additional high molecular weight compounds such as proteins (based on the filter molecular weight cutoff) throughout the growth and production phases of the culture. Various methods, such as sedimentation, centrifugation, or filtration, can be used to remove spent media, while maintaining cell density. Perfusion flow rates of a fraction of a working volume per day up to many multiple working volumes per day have been reported. An advantage of the perfusion process is that the production culture can be maintained for longer periods than batch or fed- batch culture methods. However, increased media preparation, use, storage and disposal are necessary to support a long term perfusion culture, particularly those with high cell densities, which also need even more nutrients, and all of this drives the production costs even higher, compared to batch and fed batch methods. In addition, higher cell densities can cause problems during production, such as maintaining dissolved oxygen levels and problems with increased gassing including supplying more oxygen and removing more carbon dioxide, which would result in more foaming and the need for alterations to antifoam strategies; as well as during harvest and downstream processing where the efforts required to remove the excessive cell material can result in loss of product, negating the benefit of increased titer due to increased cell mass.
Also provided is a large scale cell culture strategy that combines fed batch feeding during the growth phase followed by continuous perfusion during the production phase. The method targets a production phase where the cell culture is maintained at a packed cell volume of less than or equal to 35%. The method also provides the initiation and maintenance of cell growth-arrest due to low asparagine.
Fed batch culture is a widely -practiced culture method for large scale production of proteins from mammalian cells. See e.g. Chu and Robinson (2001), Current Opin.
Biotechnol. 12: 180-87. A fed batch culture of mammalian cells is one in which the culture is fed, either continuously or periodically, with a concentrated feed medium containing nutrients. Feeding can occur on a predetermined schedule of, for example, every day, once every two days, once every three days, etc. When compared to a batch culture, in which no feeding occurs, a fed batch culture can produce greater amounts of recombinant protein. See e.g. U.S. Patent No. 5,672,502.
In one embodiment, a fed-batch culture with bolus feeds is used to maintain a cell culture during the growth phase. Perfusion feeding can then be used during a production phase. In one embodiment, perfusion begins when the cells have reached a production phase. In another embodiment, perfusion begins on or about day 5 to on or about day 9 of the cell culture. In another embodiment perfusion begins on or about day 5 to on or about day 7 of the cell culture.
In another embodiment the initiation of cell growth-arrest in the fed-batch culture can be initiated by subjecting the fed-batch culture to a period of L-asparagine starvation followed by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5 mM or less. In one embodiment the L-asparagine concentration of the cell culture medium is monitored prior to and during L-asparagine starvation. In another embodiment the initiation of cell growth-arrest in the fed-batch culture can be achieved by perfusion with a serum free perfusion medium having an L-asparagine concentration of 5 mM or less.
Using bolus feeding during the growth phase allows the cells to transition into the production phase, resulting in less dependence on a temperature shift as a means of initiating and controlling the production phase, however a temperature shift of 36°C to 31°C can take place between the growth phase and production phase. In a preferred embodiment the shift is from 36°C to 33°C.
As described herein, the bioreactor can be inoculated with at least 0.5 xlO6 up to and beyond 3.0 xlO6 viable cells/mL in a serum-free culture medium, preferably 1.0x106 viable cells/mL.
Perfusion culture is one in which the cell culture receives fresh perfusion feed medium while simultaneously removing spent medium. Perfusion can be continuous, stepwise, intermittent, or a combination of any or all of any of these. Perfusion rates can be less than a working volume to many working volumes per day. Preferably the cells are retained in the culture and the spent medium that is removed is substantially free of cells or has significantly fewer cells than the culture. Recombinant proteins expressed by the cell culture can also be retained in the culture. Perfusion can be accomplished by a number of means including centrifugation, sedimentation, or filtration, See e.g. Voisard et al., (2003), Biotechnology and Bioengineering 82:751-65. A preferred filtration method is alternating tangential flow filtration. Alternating tangential flow is maintained by pumping medium through hollow-fiber filter modules. See e.g. US Patent No. 6,544,424; Furey (2002) Gen. Eng. News. 22 (7), 62-63.
As used herein, "perfusion flow rate" is the amount of media that is passed through (added and removed) from a bioreactor, typically expressed as some portion or multiple of the working volume, in a given time. "Working volume" refers to the amount of bioreactor volume used for cell culture. In one embodiment the perfusion flow rate is one working volume or less per day. Perfusion feed medium can be formulated to maximize perfusion nutrient concentration to minimize perfusion rate.
By "cell culture" or "culture" is meant the growth and propagation of cells outside of a multicellular organism or tissue. Suitable culture conditions for mammalian cells are known in the art. See e.g. Animal cell culture: A Practical Approach, D. Rickwood, ed., Oxford University Press, New York (1992). Mammalian cells may be cultured in suspension or while attached to a solid substrate. Fluidized bed bioreactors, hollow fiber bioreactors, roller bottles, shake flasks, or stirred tank bioreactors, with or without microcarriers, can be used. In one embodiment 500L to 2000L bioreactors are used. In a preferred embodiment, 1000L to 2000L bioreactors are used. For the purposes of this invention, cell culture medium is a media suitable for growth of animal cells, such as mammalian cells, in in vitro cell culture. Cell culture media formulations are well known in the art. Typically, cell culture media are comprised of buffers, salts, carbohydrates, amino acids, vitamins and trace essential elements. "Serum- free" applies to a cell culture medium that does not contain animal sera, such as fetal bovine serum. Various tissue culture media, including defined culture media, are commercially available, for example, any one or a combination of the following cell culture media can be used: RPMI- 1640 Medium, RPMI-1641 Medium, Dulbecco's Modified Eagle's Medium (DMEM), Minimum Essential Medium Eagle, F- 12K Medium, Ham's F12 Medium, Iscove's Modified Dulbecco's Medium, McCoy's 5A Medium, Leibovitz's L-15 Medium, and serum- free media such as EX-CELL™ 300 Series (JRH Biosciences, Lenexa, Kansas), among others. Serum-free versions of such culture media are also available. Cell culture media may be supplemented with additional or increased concentrations of components such as amino acids, salts, sugars, vitamins, hormones, growth factors, buffers, antibiotics, lipids, trace elements and the like, depending on the requirements of the cells to be cultured and/or the desired cell culture parameters.
Cell cultures can be supplemented with concentrated feed medium containing components, such as nutrients and amino acids, which are consumed during the course of the production phase of the cell culture. Concentrated feed medium may be based on just about any cell culture media formulation. Such a concentrated feed medium can contain most of the components of the cell culture medium at, for example, about 5X, 6X, 7X, 8X, 9X, 10X, 12X, 14X, 16X, 20X, 30X, 50X, lOOx, 200X, 400X, 600X, 800X, or even about 1000X of their normal amount. Concentrated feed media are often used in fed batch culture processes.
The method according to the present invention may be used to improve the production of recombinant proteins in multiple phase culture processes. In a multiple stage process, cells are cultured in two or more distinct phases. For example cells may be cultured first in one or more growth phases, under environmental conditions that maximize cell proliferation and viability, then transferred to a production phase, under conditions that maximize protein production. In a commercial process for production of a protein by mammalian cells, there are commonly multiple, for example, at least about 2, 3, 4, 5, 6, 7, 8, 9, or 10 growth phases that occur in different culture vessels preceding a final production culture. The growth and production phases may be preceded by, or separated by, one or more transition phases. In multiple phase processes, the method according to the present invention can be employed at least during the growth and production phase of the final production phase of a commercial cell culture, although it may also be employed in a preceding growth phase. A production phase can be conducted at large scale. A large scale process can be conducted in a volume of at least about 100, 500, 1000, 2000, 3000, 5000, 7000, 8000, 10,000, 15,000, 20,000 liters. In a preferred embodiment production is conducted in 500L, 1000L and/or 2000L bioreactors. A growth phase may occur at a higher temperature than a production phase. For example, a growth phase may occur at a first temperature from about 35°C to about 38°C, and a production phase may occur at a second temperature from about 29°C to about 37°C, optionally from about 30°C to about 36°C or from about 30°C to about 34°C. In addition, chemical inducers of protein production, such as, for example, caffeine, butyrate, and hexamethylene bisacetamide (HMBA), may be added at the same time as, before, and/or after a temperature shift. If inducers are added after a temperature shift, they can be added from one hour to five days after the temperature shift, optionally from one to two days after the temperature shift. The cell cultures can be maintained for days or even weeks while the cells produce the desired protein(s).
Samples from the cell culture can be monitored and evaluated using any of the analytical techniques known in the art. Variety of parameters including recombinant protein and medium quality and characteristics can be monitored for the duration of the culture. Samples can be taken and monitored intermittently at a desirable frequency, including continuous monitoring, real time or near real time. In one embodiment the L-asparagine concentration of the cell culture medium is monitored prior to and during L-asparagine starvation.
Typically the cell cultures that precede the final production culture (N-x to N- 1) are used to generate the seed cells that will be used to inoculate the production bioreactor, the N- 1 culture. The seed cell density can have a positive impact on the level of recombinant protein produced. Product levels tend to increase with increasing seed density. Improvement in titer is tied not only to higher seed density, but is likely to be influenced by the metabolic and cell cycle state of the cells that are placed into production.
Seed cells can be produced by any culture method. A preferred method is a perfusion culture using alternating tangential flow filtration. An N- 1 bioreactor can be run using alternating tangential flow filtration to provide cells at high density to inoculate a production bioreactor. The N- 1 stage may be used to grow cells to densities of >90 x 106 cells/mL. The N-1 bioreactor can be used to generate bolus seed cultures or can be used as a rolling seed stock culture that could be maintained to seed multiple production bioreactors at high seed cell density. The duration of the growth stage of production can range from 7 to 14 days and can be designed so as to maintain cells in exponential growth prior to inoculation of the production bioreactor. Perfusion rates, medium formulation and timing are optimized to grow cells and deliver them to the production bioreactor in a state that is most conducive to optimizing their production. Seed cell densities of >15 x 106 cells/mL can be achieved for seeding production bioreactors. Higher seed cell densities at inoculation can decrease or even eliminate the time needed to reach a desired production density.
The invention finds particular utility in improving cell growth, viability and/or protein production via cell culture processes. The cell lines (also referred to as "host cells") used in the invention are genetically engineered to express a polypeptide of commercial or scientific interest. Cell lines are typically derived from a lineage arising from a primary culture that can be maintained in culture for an unlimited time. Genetically engineering the cell line involves transfecting, transforming or transducing the cells with a recombinant polynucleotide molecule, and/or otherwise altering (e.g., by homologous recombination and gene activation or fusion of a recombinant cell with a non-recombinant cell) so as to cause the host cell to express a desired recombinant polypeptide. Methods and vectors for genetically engineering cells and/or cell lines to express a polypeptide of interest are well known to those of skill in the art; for example, various techniques are illustrated in Current Protocols in Molecular Biology, Ausubel et al., eds. (Wiley & Sons, New York, 1988, and quarterly updates); Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Laboratory Press, 1989); Kaufman, R.J., Large Scale Mammalian Cell Culture, 1990, pp. 15-69.
Animal cell lines are derived from cells whose progenitors were derived from a multicellular animal. One type of animal cell line is a mammalian cell line. A wide variety of mammalian cell lines suitable for growth in culture are available from the American Type Culture Collection (Manassas, Va.) and commercial vendors. Examples of cell lines commonly used in the industry include VERO, BHK, HeLa, CV1 (including Cos), MDCK, 293, 3T3, myeloma cell lines (e.g., NSO, NS 1), PC12, WI38 cells, and Chinese hamster ovary (CHO) cells. CHO cells are widely used for the production of complex recombinant proteins, e.g. cytokines, clotting factors, and antibodies (Brasel et al. (1996), Blood 88:2004-2012; Kaufman et al. (1988), J. Biol Chem 263:6352-6362; McKinnon et al. (1991), J Mol Endocrinol 6:231-239; Wood et al. (1990), J. Immunol. 145:3011-3016). The dihydrofolate reductase (DHFR)-deficient mutant cell lines (Urlaub et al. (1980), Proc Natl Acad Sci USA 77: 4216-4220), DXB 1 1 and DG-44, are desirable CHO host cell lines because the efficient DHFR selectable and amplifiable gene expression system allows high level recombinant protein expression in these cells (Kaufman R.J. (1990), Meth Enzvmol 185:537-566). In addition, these cells are easy to manipulate as adherent or suspension cultures and exhibit relatively good genetic stability. CHO cells and proteins recombinantly expressed in them have been extensively characterized and have been approved for use in clinical commercial manufacturing by regulatory agencies.
The methods of the invention can be used to culture cells that express recombinant proteins of interest. The expressed recombinant proteins may be secreted into the culture medium from which they can be recovered and/or collected. In addition, the proteins can be purified, or partially purified, from such culture or component (e.g., from culture medium) using known processes and products available from commercial vendors. The purified proteins can then be "formulated", meaning buffer exchanged, sterilized, bulk-packaged, and/or packaged for a final user. Suitable formulations for pharmaceutical compositions include those described in Remington's Pharmaceutical Sciences, 18th ed. 1995, Mack Publishing Company, Easton, PA.
As used herein "peptide," "polypeptide" and "protein" are used interchangeably throughout and refer to a molecule comprising two or more amino acid residues joined to each other by peptide bonds. Peptides, polypeptides and proteins are also inclusive of modifications including, but not limited to, glycosylation, lipid attachment, sulfation, gamma- carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation. Polypeptides can be of scientific or commercial interest, including protein-based drugs. Polypeptides include, among other things, antibodies, fusion proteins, and cytokines. Peptides, polypeptides and proteins are produced by recombinant animal cell lines using cell culture methods and may be referred to as "recombinant peptide", "recombinant polypeptide" and "recombinant protein". The expressed protein(s) may be produced intracellularly or secreted into the culture medium from which it can be recovered and/or collected.
Examples of polypeptides that can be produced with the methods of the invention include proteins comprising amino acid sequences identical to or substantially similar to all or part of one of the following proteins: tumor necrosis factor (TNF), flt3 ligand (WO 94/28391), erythropoeitin, thrombopoeitin, calcitonin, IL-2, angiopoietin-2 (Maisonpierre et al. (1997), Science 277(5322): 55-60), ligand for receptor activator of NF-kappa B (RANKL, WO 01/36637), tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, WO 97/01633), thymic stroma-derived lymphopoietin, granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor (GM-CSF, Australian Patent No. 588819), mast cell growth factor, stem cell growth factor (US Patent No.6,204,363), epidermal growth factor, keratinocyte growth factor, megakaryote growth and development factor, RANTES, human fibrinogen- like 2 protein (FGL2; NCBI accession no. NM 00682; Ruegg and Pytela (1995), Gene 160:257-62) growth hormone, insulin, insulinotropin, insulin- like growth factors, parathyroid hormone, interferons including a-interferons, γ-interferon, and consensus interferons (US Patent Nos. 4,695,623 and 4,897471), nerve growth factor, brain-derived neurotrophic factor, synaptotagmin-like proteins (SLP 1-5), neurotrophin-3, glucagon, interleukins, colony stimulating factors, lymphotoxin-β, leukemia inhibitory factor, and oncostatin-M. Descriptions of proteins that can be produced according to the inventive methods may be found in, for example, Human Cytokines: Handbook for Basic and Clinical Research, all volumes (Aggarwal and Gutterman, eds. Blackwell Sciences, Cambridge, MA, 1998); Growth Factors: A Practical Approach (McKay and Leigh, eds., Oxford University Press Inc., New York, 1993); and The Cytokine Handbook. Vols. 1 and 2 (Thompson and Lotze eds., Academic Press, San Diego, CA, 2003).
Additionally the methods of the invention would be useful to produce proteins comprising all or part of the amino acid sequence of a receptor for any of the above- mentioned proteins, an antagonist to such a receptor or any of the above-mentioned proteins, and/or proteins substantially similar to such receptors or antagonists. These receptors and antagonists include: both forms of tumor necrosis factor receptor (TNFR, referred to as p55 and p75, US Patent No. 5,395,760 and US Patent No. 5,610,279), Interleukin- 1 (IL- 1) receptors (types I and II; EP Patent No. 0460846, US Patent No. 4,968,607, and US Patent No. 5,767,064,), IL-1 receptor antagonists (US Patent No. 6,337,072), IL- 1 antagonists or inhibitors (US Patent Nos. 5,981,713, 6,096,728, and 5,075,222) IL-2 receptors, IL-4 receptors (EP Patent No. 0 367 566 and US Patent No. 5,856,296), IL- 15 receptors, IL- 17 receptors, IL-18 receptors, Fc receptors, granulocyte-macrophage colony stimulating factor receptor, granulocyte colony stimulating factor receptor, receptors for oncostatin-M and leukemia inhibitory factor, receptor activator of NF-kappa B (RANK, WO 01/36637 and US Patent No. 6,271,349), osteoprotegerin (US. Patent No. 6,015,938), receptors for TRAIL (including TRAIL receptors 1, 2, 3, and 4), and receptors that comprise death domains, such as Fas or Apoptosis-Inducing Receptor (AIR).
Other proteins that can be produced using the invention include proteins comprising all or part of the amino acid sequences of differentiation antigens (referred to as CD proteins) or their ligands or proteins substantially similar to either of these. Such antigens are disclosed in Leukocyte Typing VI (Proceedings of the Vlth International Workshop and Conference, Kishimoto, Kikutani et al., eds., Kobe, Japan, 1996). Similar CD proteins are disclosed in subsequent workshops. Examples of such antigens include CD22, CD27, CD30, CD39, CD40, and ligands thereto (CD27 ligand, CD30 ligand, etc.). Several of the CD antigens are members of the TNF receptor family, which also includes 4 IBB and OX40. The ligands are often members of the TNF family, as are 4 IBB ligand and OX40 ligand.
Enzymatically active proteins or their ligands can also be produced using the invention. Examples include proteins comprising all or part of one of the following proteins or their ligands or a protein substantially similar to one of these: a disintegrin and metalloproteinase domain family members including TNF-alpha Converting Enzyme, various kinases, glucocerebrosidase, superoxide dismutase, tissue plasminogen activator, Factor VIII, Factor IX, apolipoprotein E, apolipoprotein A-I, globins, an IL-2 antagonist, alpha- 1 antitrypsin, ligands for any of the above-mentioned enzymes, and numerous other enzymes and their ligands.
The term "antibody" includes reference to both glycosylated and non-glycosylated immunoglobulins of any isotype or subclass or to an antigen-binding region thereof that competes with the intact antibody for specific binding, unless otherwise specified, including human, humanized, chimeric, multi-specific, monoclonal, polyclonal, and oligomers or antigen binding fragments thereof. Also included are proteins having an antigen binding fragment or region such as Fab, Fab', F(ab')2, Fv, diabodies, Fd, dAb, maxibodies, single chain antibody molecules, complementarity determining region (CDR) fragments, scFv, diabodies, triabodies, tetrabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to a target polypeptide. The term "antibody" is inclusive of, but not limited to, those that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from a host cell transfected to express the antibody.
Examples of antibodies include, but are not limited to, those that recognize any one or a combination of proteins including, but not limited to, the above-mentioned proteins and/or the following antigens: CD2, CD3, CD4, CD8, CDl la, CD14, CD18, CD20, CD22, CD23, CD25, CD33, CD40, CD44, CD52, CD80 (B7.1), CD86 (B7.2), CD 147, IL-la, IL-Ιβ, IL-2, IL-3, IL-7, IL-4, IL-5, IL-8, IL-10, IL-2 receptor, IL-4 receptor, IL-6 receptor, IL-13 receptor, IL- 18 receptor subunits, FGL2, PDGF-β and analogs thereof (see US Patent Nos. 5,272,064 and 5, 149,792), VEGF, TGF, TGF- 2, TGF-βΙ, EGF receptor (see US Patent No. 6,235,883) VEGF receptor, hepatocyte growth factor, osteoprotegerin ligand, interferon gamma, B lymphocyte stimulator (BlyS, also known as BAFF, THANK, TALL- 1, and zTNF4; see Do and Chen-Kiang (2002), Cytokine Growth Factor Rev. 13(1): 19-25), C5 complement, IgE, tumor antigen CA125, tumor antigen MUC1, PEM antigen, LCG (which is a gene product that is expressed in association with lung cancer), HER-2, HER-3, a tumor-associated glycoprotein TAG-72, the SK-1 antigen, tumor-associated epitopes that are present in elevated levels in the sera of patients with colon and/or pancreatic cancer, cancer-associated epitopes or proteins expressed on breast, colon, squamous cell, prostate, pancreatic, lung, and/or kidney cancer cells and/or on melanoma, glioma, or neuroblastoma cells, the necrotic core of a tumor, integrin alpha 4 beta 7, the integrin VLA-4, B2 integrins, TRAIL receptors 1, 2, 3, and 4, RANK, RANK ligand, TNF-a, the adhesion molecule VAP- 1, epithelial cell adhesion molecule (EpCAM), intercellular adhesion molecule-3 (ICAM-3), leukointegrin adhesin, the platelet glycoprotein gp Ilb/IIIa, cardiac myosin heavy chain, parathyroid hormone, rNAPc2 (which is an inhibitor of factor Vila-tissue factor), MHC I, carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), tumor necrosis factor (TNF), CTLA-4 (which is a cytotoxic T lymphocyte-associated antigen), Fc-γ-Ι receptor, HLA-DR 10 beta, HLA-DR antigen, sclerostin, L-selectin, Respiratory Syncitial Virus, human immunodeficiency virus (HIV), hepatitis B virus (HBV), Streptococcus mutans, and Staphlycoccus aureus. Specific examples of known antibodies which can be produced using the methods of the invention include but are not limited to adalimumab, bevacizumab, infliximab, abciximab, alemtuzumab, bapineuzumab, basiliximab, belimumab, briakinumab, canakinumab, certolizumab pegol, cetuximab, conatumumab, denosumab, eculizumab, gemtuzumab ozogamicin, golimumab, ibritumomab tiuxetan, labetuzumab, mapatumumab, matuzumab, mepolizumab, motavizumab, muromonab-CD3, natalizumab, nimotuzumab, ofatumumab, omalizumab, oregovomab, palivizumab, panitumumab, pemtumomab, pertuzumab, ranibizumab, rituximab, rovelizumab, tocilizumab, tositumomab, trastuzumab, ustekinumab, vedolizomab, zalutumumab, and zanolimumab.
The invention can also be used to produce recombinant fusion proteins comprising, for example, any of the above-mentioned proteins. For example, recombinant fusion proteins comprising one of the above-mentioned proteins plus a multimerization domain, such as a leucine zipper, a coiled coil, an Fc portion of an immunoglobulin, or a substantially similar protein, can be produced using the methods of the invention. See e.g. WO94/10308; Lovejoy et al. (1993), Science 259: 1288-1293; Harbury et al. (1993), Science 262: 1401-05; Harbury et al. (1994), Nature 371 :80-83; Hakansson et al.(1999), Structure 7:255-64. Specifically included among such recombinant fusion proteins are proteins in which a portion of a receptor is fused to an Fc portion of an antibody such as etanercept (a p75 TNFR:Fc), and belatacept (CTLA4:Fc).
While the terminology used in this application is standard within the art, definitions of certain terms are provided herein to assure clarity and definiteness to the meaning of the claims. Units, prefixes, and symbols may be denoted in their SI accepted form. Numeric ranges recited herein are inclusive of the numbers defining the range and include and are supportive of each integer within the defined range. The methods and techniques described herein are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, e.g., Sambrook et al. Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2001) and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992), and Harlow and Lane Antibodies: A Laboratory Manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1990). All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference. What is described in an embodiment of the invention can be combined with other embodiments of the invention.
The present invention is not to be limited in scope by the specific embodiments described herein that are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.
EXAMPLES
Example 1
This experiment compares different start up conditions using batch or fed batch feeding methods followed by continuous perfusion using alternating tangential flow filtration. Perfusion was started either early during the early exponential growth phase ("batch" start up) with no additional feeds prior to perfusion or at the end of the exponential phase and entering into the stationary or production phase ("fed-batch" start up) receiving several bolus feeds of a serum-free defined feed media prior to perfusion.
On day 0, CHO cells expressing a recombinant antibody were inoculated into 2L production bioreactors at lxlO6 viable cells/mL in a working volume of 1500 ml of a serum- free defined medium for the fed-batch start and 1800mL for the batch start. Cultures were maintained at 36°C, dissolved oxygen (DO) at 30%, agitation at 215 RPM. Glucose was maintained above 0 g/L and below 8 g/L.
Perfusion was started on day 4 (0.25 Vol/day) for the batch cultures and on day 7
(0.75 Vol/day) for the fed-batch cultures. Perfusion was accomplished using an alternating tangential flow perfusion and filtration system (Refine Technologies, Hanover, NJ, 50 kDa hollow fiber filter). Prior to starting perfusion the fed-batch cultures received bolus feeds of a concentrated serum-free defined feed media on day 4 (7.5% of initial working volume) and day 6 (10% initial working volume). Perfusion rates are provided in Table 1.
Table 1. Perfusion Rate
Perfusion Rate
Day
(Vol/day)
0 - 4* 0.00 4 - 6 0.25
6 - 7 0.50
7 - 10 0.75
10 - 1.00
Values are based on working volumes disclosed above
*Day 0-7 for the fed batch start
During the culture run, daily samples were taken to assess the culture. Viable cell density (VCD) and viability were determined using Vi-Cell (Beckman Coulter, Brea, CA). Titer was measured by HPLC analysis. Packed cell volume was determined using VoluPAC (Sartorius, Goettingen, Germany).
A temperature shift (36.0°C to 33.0°C) was applied when the viable cell density exceeded 20 x 106 viable cells/mL which was day 7 and day 11 for the batch and fed-batch start conditions respectively.
For the batch start-up conditions, the viable cell density continued to increase after the perfusion was started; for the fed-batch start conditions, the perfusion was started after the cell culture had reached a plateau or stationary phase with little growth. On day 15, the viable cell density for the fed batch was between 27.7 and 30.7 x 106 viable cells/mL while VCD of the batch culture was between 22.5 and 27.4 x 106 viable cells/mL (Figure 1A). Viability of the fed batch culture was between 73.9 and 77.5% while the batch culture viability was between 72.5 and 83.1% (Figure IB). The titer of the fed batch culture was between 15.3 and 16.1 g/L while the batch culture titer was between 10.6 and 12.3 g/L (Figure 1C). Since the integrated variable cell density (IVCD) values were similar for all four cultures by day 15 (approximately 230 x 106 cell days/mL), the specific productivity was higher in the fed-batch start-up conditions. The fed batch cultures were continued to day 24. A titer of 20 g/L was achieved at 20 days.
The alternating tangential flow perfusion with a fed batch start-up resulted in increased productivity, maintaining the cells in a more productive state compared to the batch start method.
Example 2
On day 0, CHO cells expressing a recombinant antibody were inoculated into 2L production bioreactors at lxlO6 viable cells/mL in a working volume of 1500 ml of a serum- free defined medium for the batch start and 1300mL for the fed-batch start. Cultures were maintained at 36°C, DO at 30%, agitation at 215 RPM for batch cultures. The fed-batch culture was agitated at 430RPM. Fed-batch culture was fed to 7 g/L glucose daily prior to perfusion and all cultures were maintained at or above 4 g/L glucose during perfusion. Perfusion (alternating tangential flow) was started on day 4 (0.25 Vol/day) for the batch cultures and on day 8 (0.75 Vol/day) for the fed-batch culture. Prior to starting perfusion the fed-batch culture received bolus feeds of a concentrated serum-free defined feed media on day 4 (7.5% of initial working volume) and day 6 (10% initial working volume). Perfusion flow rates settings are provided in Table 2. The cultures were maintained for 21 days.
Table 2. Perfusion Rate
Perfusion Rate
Day
(Vol/day)
4 - 6 0.25
6 - 8 0.50
8 - 10 0.75
10 - 1.00
Values are based on working volumes disclosed above
During the culture run daily samples were taken as described above to assess the culture.
A temperature shift (36.0°C to 33.0°C) was applied to the batch cultures on day 6 when the viable cell density exceeded 20 x 106 viable cells/mL, as in Example 1. The fed batch culture was maintained at 36.0°C for the duration of the culture.
The batch start-up method cultures had results similar to those described above with the cells reaching approximately 20 to 25 x 106 viable cells/mL with no growth after day 10. The fed-batch culture reached almost 30 x 106 viable cells/mL on day 20 after spending most of the culture duration below 20 x 106 viable cells/mL, see Figure 2A. The viabilities all remained above 80% until day 10 and then dropping to about 40% by day 20 for the batch start cultures and 60% for the fed-batch culture, see Figure 2B. The titer peaked at almost 15 g/L for the batch start cultures, but it reached over 20 g/L for the high agitation fed-batch culture, see Figure 2C. It was observed that the batch start cultures had an L-asparagine concentration of about 3 to 4mM on day 3, and did not experience an asparagine limited culture environment. However, the fed-batch perfusion start culture experienced an L- asparagine limited environment by day 6 prior to the start of the perfusion on day 7. The culture was then perfused with medium containing L-asparagine at a concentration of 2.0 g/L (or 13.3 mM) that resulted in no further L-asparagine limitations after day 8 (Figure 2D). Glucose concentrations were maintained mostly between 4 and 10 g/L. The fed-batch start-up with high agitation perfusion culture achieved the highest titer (over 20 g/L) in 20 days, more than 5 g/L higher than the batch start-up cultures, which was similar to the results described above. No negative effects of a higher agitation rate were observed. Maintaining a constant temperature did not appear to negatively impact the fed batch culture.
Example 3
This experiment characterizes the effects of perfusion volume and temperature shifts on an alternating tangential flow perfusion with a fed batch start-up as described above. All cultures were fed-batch start with perfusion beginning on day 7. Perfusion flow rates moving from three-quarter working volumes to full volume or from full working volume to three- quarter working volume were tested. A temperature shift from 36°C to 33°C on Day 14 was also tested.
On day 0, CHO cells expressing a recombinant antibody were inoculated into 2L production bioreactors at lxlO6 cells/mL in a working volume of 1200 ml of a serum- free defined medium. Cultures were maintained at 36°C, DO at 30%. Prior to perfusion, glucose was fed to 7 g/L daily and during perfusion glucose was maintained above 1 g/L. The culture was maintained for 20 days.
Cultures received bolus feeds of a concentrated serum- free defined feed media on day 4 (7.5% of initial working volume) and day 6 (10% initial working volume). Perfusion began on Day 8. Perfusion rates are provided in Table 3. One culture from each group had a temperature shift from 36°C to 33°C on Day 15, the other cultures remained at 36°C for the duration of the experiment
Table 3. Perfusion Rate
Perfusion Rate
Condition Day
(Vol/day)
Condition 1 8 - 12 0.75
(n=2) 12 - 1.00
Condition 2 8 - 10 1.00
(n=2) 10 - 0.75
Values are based on working volumes disclosed above
Temperature shift and perfusion rate did not impact viable cell density, see Figure 3A. However, a temperature shift appears to help preserve viability at later time points in a culture. There appears to be a break out between the temperatures shift conditions starting on Day 15 onward. The viability of the temperature shifted cultures dropped more slowly than the cultures that remained at 36°C, see Figure 3B. As for titer, three cultures showed very similar titers on Day 15 (17.1-17.9 g/L) as well as on Day 20 (22-24 g/L), but one culture had a higher titer on Day 15 (21.58 g/L) as well as on Day 20 (28.33 g/L) (see Figure 3C). Neither the temperature nor perfusion rates appeared to have any impact on titer production, suggesting that cultures can be maintained with different perfusion rates.
Example 4
This experiment was designed to investigate the effects of perfusion medium asparagine concentrations and perfusion start conditions with either L-asparagine limited or non-limited culture environments on viable cell density during the production phase.
On day 0, CHO cells expressing a recombinant antibody were inoculated into 2L production bioreactors at lxl 06 cells/mL in a working volume of 1500 ml for both the batch and fed-batch start methods. Cultures were maintained at 36°C, dissolved oxygen (DO) at 30%, agitation at 400 RPM. Sparging was done using either a drilled pipe or a sintered sparger. Glucose was maintained above 0 g/L and below 8 g/L.
Perfusion (alternating tangential flow) was started on day 3 (0.29 Vol/day) for the batch start "non-asparagine-limited cultures" and on day 7 (0.48 Vol/day) for the fed-batch "asparagine-limited cultures". The batch culture medium contained lOmM L-asparagine. Prior to starting perfusion the fed-batch cultures received bolus feeds of a concentrated serum-free defined feed media on days 3 and 6 (7% initial working volume) containing 1 13.4mM L-asparagine. Perfusion medium asparagine concentrations were either at a control concentration (17.3mM Asn in a serum free defined perfusion medium) or a low concentration (5mM Asn in a serum free defined perfusion medium). Perfusion was carried out as described above. Perfusion rates are provided in Table 4.
Table 4. Perfusion Rates
Perfusion Rate
Condition Day
(Vol/day)
Day 3 3 - 4 0.29
Batch 4 - 7 0.48
Perfusion
Start 7 - 9 0.48
non- 9 - 11 0.67
asparagine- limited 1 1 - 20 0.96
culture Day 7 7 - 9 0.48
Fed-Batch 9 - 11 0.67
Perfusion
Start
asparagine- 1 1 - 20 0.96
limited
culture
During the culture run, daily samples were taken to assess the culture. Viable cell density (VCD) and viability were determined using Vi-Cell (Beckman Coulter, Brea, CA). Titer was measured by HPLC analysis. All cultures were maintained at 36.0°C.
Reduction in cell growth and improved productivity was achieved during the production phase by limiting asparagine in the culture medium. On day 15, the maximum viable cell density was about 17.0 x 106 viable cells/mL for the fed-batch start cultures with low asparagine (Figure 4A). Control level asparagine cultures reached viable cell densities exceeding 40x106 viable cells/mL (>30% packed cell volume). Viability of the low asparagine fed-batch culture was 67.1% while the batch culture viability was 55.1% and the control was 69% (Figure 4B). The packed cell volume adjusted titer of the low asparagine fed-batch culture was 17.0 g/L (adjusted for packed cell volume) while the batch culture titer was between 15.4 g/L (Figure 4C). The controls had titers of 10.2 to 12.9 g/L (batch start) and 14.2 to 15.9 g/L (fed-batch start).
Maintaining asparagine levels at 5mM or less during the production resulted in growth-arrest, stimulated productivity and maintained viability during the production phase.
Example: 5
This experiment compares media conditions during perfusion. In this 2L bioreactor experiment, cells were inoculated into a chemically defined batch medium at a working volume of 1.5L, cultured for 3 days and then perfused for 12 days using a chemically defined perfusion medium containing either 17.3 mM L-asparagine and 4.6 mM L-glutamine or 5 mM L-asparagine and 10 mM L-glutamine. Perfusion was accomplished using an alternating tangential flow perfusion and filtration system (Refine Technologies, Hanover, NJ) with a 30 kDa hollow fiber filter (GE Healthcare, Little Chalfont, UK). Perfusion was started on day 3 at a rate of 0.3 culture volumes per day. The rate of perfusion was increased on days 4, 9, and 1 1 as indicated in Table 6 below. Cultures were maintained at 36°C, DO at 30%, pH at 7.0, and agitation at 400 rpm.
During the culture run, daily samples were taken to assess the culture. Viable cell density
(VCD) and viability were determined using Vi-Cell (Beckman Coulter, Brea, CA). Titer was measured by HPLC analysis. Packed cell volume was determined using VoluPAC (Sartorius, Goettingen, Germany).
Table 5. Perfusion rate schedule
Day Perfusion Rate (Vol/day)
3 0.30
4 0.50
9 0.67
1 1 0.96
Asparagine limitation resulted in the accumulation of fewer cells and improved productivity. Cultures perfused with media containing 5 mM asparagine reached a maximum VCD of 8.16 x 107 - 8.54 x 107 cells/mL while cultures perfused with media containing 17.3 mM asparagine reached 1 1.9 x 107 - 12.2 x 107 cells/mL (Figure 5A). Although the cultures in 17.3 mM asparagine had more cells, the cultures in 5 mM asparagine made more product. Cultures perfused with media containing 17.3 mM asparagine made 6.89-7.18 g/L (4.33 - 4.67 g/L packed cell volume adjusted) compared to 7.59-8.15 g/L (5.01 - 5.38 g/L packed cell volume adjusted) for cultures perfused with media containing 5 mM asparagine (Figures 5B and 5D). The final packed cell volume (PCV) of the 5mM asparagine cultures trended slightly lower than the 17.3 mM asparagine cultures (Figure 5C) and there was no difference in culture viability (Figure 5E).
Interestingly, in this example increasing the concentration of glutamine by more than two-fold in the low-asparagine condition (4.6 mM versus 10 mM glutamine) did not interfere with the ability of the low-asparagine medium to arrest the growth of the culture.
Example 6
This example compares the performance of a clonal, antibody-expressing CHO cell line cultured in an ATF perfusion process using asparagine limitation to control growth at bench and pilot scales. The bench-scale model utilized 2L bioreactors and the pilot scale was 500L. At bench scale, cells were inoculated into a chemically defined batch medium at a working volume of 1.5L and at pilot scale the working volume was about 378L. Cells were cultured for 3 days in the batch medium and then perfused for 12 days using a chemically defined perfusion medium containing 5 mM L-asparagine and 10 mM L-glutamine. Perfusion was accomplished using an alternating tangential flow perfusion and filtration system (Refine Technologies, Hanover, NJ) with a 30 kDa hollow fiber filter (GE Healthcare, Little Chalfont, UK). Perfusion was started on day 3 at a rate of 0.3 culture volumes per day. The rate of perfusion was increased on days 4, 9, and 1 1 as indicated in Table 7 below. Cultures were maintained at 36°C, 30% DO, and pH 6.9.
During the culture run, daily samples were taken to assess the culture. Viable cell density (VCD) and viability were determined bench scale using Vi-Cell (Beckman Coulter, Brea, CA) and at pilot scale using a CEDEX (Roche Applied Science, Indianapolis, IN). Titer was measured by HPLC analysis. Packed cell volume was determined using VoluPAC (Sartorius, Goettingen, Germany). Table 6. Perfusion rate schedule
Day Perfusion Rate (Vol/day)
3 0.30
4 0.50
9 0.67
1 1 0.96
Data from four bench scale cultures and two pilot scale cultures is provided. VCD curves were similar at both scales, growth control was achieved (Figure 6A), and the total cell mass (packed cell volume) was maintained below 30% at both scales (Figure 6C). Although the VCD reached a plateau around day 10 or day 11, the packed cell volume continued to increase until about day 13 or 14 (Figure 6C). Productivity was also similar between scales. Cultures perfused with media containing 5 mM asparagine made 14.2 - 15.7 g/L (10.7 - 1 1.4 g/L packed cell volume adjusted) at 2L bench scale compared to 15.0 - 17.3 g/L (10.6 - 12.8 g/L packed cell volume adjusted) at 500L pilot scale (Figures 6B and 6D). Viability trended slightly lower at the pilot scale (Figure 6E).

Claims

What is claimed is:
1. A method of arresting cell growth in a mammalian cell culture expressing a recombinant protein comprising
establishing a mammalian cell culture in a serum- free culture medium in a bioreactor; inducing cell growth-arrest by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less;
maintaining the mammalian cells in a growth-arrested state by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less.
2. A method of increasing recombinant protein production in a mammalian cell culture expressing a recombinant protein comprising
establishing a mammalian cell culture in a serum- free culture medium in a bioreactor; inducing cell growth-arrest by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less;
maintaining the mammalian cells in a growth-arrested state by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less.
3. A method of limiting a mammalian cell culture expressing a recombinant protein at a desired packed cell volume comprising
establishing a mammalian cell culture in a serum- free culture medium in a bioreactor, inducing cell growth-arrest by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less,
maintaining the mammalian cells in a growth-arrested state by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5mM or less.
4. The method of any of claims 1-3, wherein the perfusion with a serum- free perfusion medium having an L-asparagine concentration of 5mM or less begins on or before day 3 of the culture.
5. The method according to any of claims 1-3, wherein induction of cell growth-arrest takes place prior to a production phase.
6. The method according to any of claims 1-3, wherein induction of cell growth-arrest takes place during a production phase.
7. The method according to any of claims 1-3, wherein cell growth-arrest is induced by L- asparagine starvation.
8. The method according to any of claims 1-3, further comprising a temperature shift from 36°C to 31°C.
9. The method according to any of claims 1-3, further comprising a temperature shift from 36°C to 33°C.
10. The method according to claims 8 or 9, wherein the temperature shift occurs at the transition between a growth phase and a production phase.
1 1. The method according to claims 8 or 9, wherein the temperature shift occurs during a production phase.
12. A method of culturing mammalian cells expressing a recombinant protein comprising; establishing a mammalian cell culture in a serum- free culture medium in a bioreactor; growing the mammalian cells during a growth phase and supplementing the culture medium with bolus feeds of a serum-free feed medium, and
maintaining the mammalian cells during a production phase by perfusion with a serum- free perfusion medium, wherein the packed cell volume during the production phase is less than or equal to 35%.
13. The method according to claim 12, wherein perfusion begins on or about day 5 to on or about day 9 of the cell culture.
14. The method according to claim 12 or 13, wherein perfusion begins on or about day 5 to on or about day 7 of the cell culture.
15. The method according to claim 12, wherein perfusion begins when the cells have reached a production phase.
16. The method according to claim 12, further comprising inducing cell growth-arrest by L- asparagine starvation followed by perfusion with a serum-free perfusion medium having an L-asparagine concentration of 5 mM or less.
17. The method according to claim 12, further comprising inducing cell growth-arrest by perfusion with a serum- free perfusion medium having an L-asparagine concentration of 5 mM or less.
18. The method according to any of claims 1-3, 16 and 17, wherein the concentration of L- asparagine in the serum- free perfusion medium is less than or equal to 5mM.
19. The method according to any of claims 1-3 and 16-18, wherein the concentration of L- asparagine in the serum-free perfusion medium is less than or equal to 4.0 mM.
20. The method according to any of claims 1-3 and 16-19, wherein the concentration of L- asparagine in the serum- free perfusion medium is less than or equal to 3.0 mM.
21. The method according to any of claims 1 -3 and 16-20, wherein the concentration of L- asparagine in the serum-free perfusion medium is less than or equal to 2.0 mM.
22. The method according to any of claims 1-3 and 16-21, wherein the concentration of L- asparagine in the serum- free perfusion medium is less than or equal to 1.0 mM.
23. The method according to any of claims 1-3 and 16-22, wherein the concentration of L- asparagine in the serum- free perfusion medium is 0 mM.
24. The method according to claim 7 or 16, wherein the L-asparagine concentration of the cell culture medium is monitored prior to and during L-asparagine starvation.
25. The method according to any of claims 1-3, further comprising wherein the packed cell volume during a production phase is less than or equal to 35%
26. The method according to claim 12 or 25, wherein the packed cell volume is less than or equal to 35%.
27. The method according to any of claims 12, 25 and 26, wherein the packed cell volume is less than or equal to 30%.
28. The method according to claim 12 or 25, wherein the viable cell density of the mammalian cell culture at a packed cell volume less than or equal to 35 % is l OxlO6 viable cells/ml to 80x106 viable cells/ml.
29. The method according to claim 28, wherein the viable cell density of the mammalian cell culture is 20x106 viable cells/ml to 30xl06 viable cells/ml.
30. The method according to any of claims 1-3 and 12, wherein perfusion comprises continuous perfusion.
31. The method according to any of claims 1-3 and 12, wherein the rate of perfusion is constant.
32. The method according to any of claims 1-3 and 12, wherein perfusion is performed at a rate of less than or equal to 1.0 working volumes per day.
33. The method according to any of claims 1-3 and 12, wherein perfusion is performed at a rate that increases during the production phase from 0.25 working volume per day to 1.0 working volume per day during the cell culture.
34. The method according to claim 12, wherein perfusion is performed at a rate that reaches 1.0 working volume per day on day 9 to day 1 1 of the cell culture.
35. The method according to claim 12 or 34, wherein perfusion is performed at a rate that reaches 1.0 working volume per day on day 10 of the cell culture.
36. The method according to claim 12, wherein the bolus feeds of serum-free feed medium begin on day 3 or day 4 of the cell culture.
37. The method according to any of claims 1-3 and 12, wherein the mammalian cell culture is established by inoculating the bioreactor with at least 0.5 x 106 to 3.0 x 106 cells/mL in a serum-free culture medium.
38. The method according to any of claims 1-3, 12 and 37, wherein the mammalian cell culture is established by inoculating the bioreactor with at least 0.5 x 106 to 1.5 x 106 cells/mL in a serum-free culture medium.
39. The method according to claim 12, further comprising a temperature shift from 36°C to 31°C.
40. The method according to claim 12, further comprising a temperature shift from 36°C to 33°C.
41. The method according to claim 39 or 40, wherein the temperature shift occurs at the transition between the growth phase and production phase.
42. The method according to claim 39 or 40, wherein the temperature shift occurs during the production phase.
43. The method according to any of claims 1-3 and 12, wherein the perfusion is accomplished by alternating tangential flow.
44. The method according any of claims 1-3 and 12, wherein the bioreactor has a capacity of at least 500L.
45. The method according to any of claims 1-3, 12 and 44, wherein the bioreactor has a capacity of at least 500L to 2000L.
46. The method according to any of claims 1-3, 12, 44 and 45, wherein the bioreactor has a capacity of at least 1000L to 2000L.
47. The method according any of claims 1-3 and 12, wherein the mammalian cells are Chinese Hamster Ovary (CHO) cells.
48. The method according any of claims 1-3 and 12, wherein the recombinant protein is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a recombinant fusion protein, or a cytokine.
49. The method any of claims 1-3 and 12, further comprising a step of harvesting the recombinant protein produced by the cell culture.
50. The method any of claims 1-3 and 12, wherein the recombinant protein produced by the cell culture is purified and formulated in a pharmaceutically acceptable formulation.
51. The method of claim 2, wherein recombinant protein production in the mammalian cell culture is increased compared to a culture where the cells are not subjected to L-asparagine- induced cell growth-arrest.
PCT/US2012/045070 2011-07-01 2012-06-29 Mammalian cell culture WO2013006479A2 (en)

Priority Applications (39)

Application Number Priority Date Filing Date Title
EP14187232.5A EP2837680B1 (en) 2011-07-01 2012-06-29 Mammalian cell culture
BR112013033730-3A BR112013033730B1 (en) 2011-07-01 2012-06-29 Method for culturing mammalian cells expressing recombinant protein
ES12738674.6T ES2625045T3 (en) 2011-07-01 2012-06-29 Mammalian cell culture
IL310968A IL310968A (en) 2011-07-01 2012-06-29 Mammalian cell culture
CN201711406697.2A CN107988166B (en) 2011-07-01 2012-06-29 Mammalian cell culture
EA201391826A EA039023B1 (en) 2011-07-01 2012-06-29 Mammalian cell culture
MX2013014937A MX351974B (en) 2011-07-01 2012-06-29 Mammalian cell culture.
US14/127,050 US11292829B2 (en) 2011-07-01 2012-06-29 Mammalian cell culture
JP2014519184A JP5897708B2 (en) 2011-07-01 2012-06-29 Mammalian cell culture
CA2838695A CA2838695C (en) 2011-07-01 2012-06-29 Mammalian cell culture
SI201230945A SI2726600T1 (en) 2011-07-01 2012-06-29 Mammalian cell culture
KR1020187012639A KR102108663B1 (en) 2011-07-01 2012-06-29 Mammalian cell culture
DK12738674.6T DK2726600T3 (en) 2011-07-01 2012-06-29 Mammalian Cell Culture
PL14187232T PL2837680T3 (en) 2011-07-01 2012-06-29 Mammalian cell culture
IL297998A IL297998B2 (en) 2011-07-01 2012-06-29 Mammalian cell culture
KR1020147001985A KR101662412B1 (en) 2011-07-01 2012-06-29 Mammalian cell culture
EP12738674.6A EP2726600B1 (en) 2011-07-01 2012-06-29 Mammalian cell culture
KR1020237043604A KR20240005106A (en) 2011-07-01 2012-06-29 Mammalian cell culture
CN201280032874.4A CN103827292B (en) 2011-07-01 2012-06-29 Mammaliancellculture
KR1020237024499A KR20230114317A (en) 2011-07-01 2012-06-29 Mammalian cell culture
KR1020167015700A KR101857380B1 (en) 2011-07-01 2012-06-29 Mammalian cell culture
AU2012279230A AU2012279230B2 (en) 2011-07-01 2012-06-29 Mammalian cell culture
BR122021007265-5A BR122021007265B1 (en) 2011-07-01 2012-06-29 Methods for culturing cho mammalian cells expressing a recombinant protein
KR1020227003428A KR102558247B1 (en) 2011-07-01 2012-06-29 Mammalian cell culture
IL288509A IL288509B2 (en) 2011-07-01 2012-06-29 Mammalian cell culture
KR1020207012533A KR102358951B1 (en) 2011-07-01 2012-06-29 Mammalian cell culture
LTEP12738674.6T LT2726600T (en) 2011-07-01 2012-06-29 Mammalian cell culture
IL229803A IL229803B (en) 2011-07-01 2013-12-05 Mammalian cell culture
ZA2013/09372A ZA201309372B (en) 2011-07-01 2013-12-10 Mammalian cell culture
HK14110449A HK1197081A1 (en) 2011-07-01 2014-10-20 Mammalian cell culture
CY20171100366T CY1118863T1 (en) 2011-07-01 2017-03-22 Mammalian Cultivation
CY20201100473T CY1123146T1 (en) 2011-07-01 2020-05-25 MAMMALIAN CELL CULTURE
US17/018,564 US11673941B2 (en) 2011-07-01 2020-09-11 Mammalian cell culture
US17/018,557 US11634476B2 (en) 2011-07-01 2020-09-11 Mammalian cell culture
IL278430A IL278430B (en) 2011-07-01 2020-11-02 Mammalian cell culture
US17/686,766 US20220185869A1 (en) 2011-07-01 2022-03-04 Mammalian cell culture
US18/066,251 US11685772B2 (en) 2011-07-01 2022-12-14 Mammalian cell culture
US18/068,922 US20230129523A1 (en) 2011-07-01 2022-12-20 Mammalian cell culture
US18/180,828 US11827692B2 (en) 2011-07-01 2023-03-08 Mammalian cell culture

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161503737P 2011-07-01 2011-07-01
US61/503,737 2011-07-01

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US14/127,050 A-371-Of-International US11292829B2 (en) 2011-07-01 2012-06-29 Mammalian cell culture
US17/018,564 Division US11673941B2 (en) 2011-07-01 2020-09-11 Mammalian cell culture
US17/018,557 Division US11634476B2 (en) 2011-07-01 2020-09-11 Mammalian cell culture
US17/686,766 Continuation US20220185869A1 (en) 2011-07-01 2022-03-04 Mammalian cell culture

Publications (2)

Publication Number Publication Date
WO2013006479A2 true WO2013006479A2 (en) 2013-01-10
WO2013006479A3 WO2013006479A3 (en) 2013-03-28

Family

ID=46579326

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/045070 WO2013006479A2 (en) 2011-07-01 2012-06-29 Mammalian cell culture

Country Status (24)

Country Link
US (7) US11292829B2 (en)
EP (2) EP2726600B1 (en)
JP (1) JP5897708B2 (en)
KR (7) KR20240005106A (en)
CN (2) CN107988166B (en)
AU (5) AU2012279230B2 (en)
BR (2) BR122021007265B1 (en)
CA (2) CA2952347A1 (en)
CL (2) CL2013003792A1 (en)
CY (2) CY1118863T1 (en)
DK (2) DK2726600T3 (en)
EA (1) EA039023B1 (en)
ES (2) ES2788132T3 (en)
HK (2) HK1197081A1 (en)
HU (2) HUE033279T2 (en)
IL (5) IL297998B2 (en)
LT (2) LT2837680T (en)
MX (1) MX351974B (en)
PL (2) PL2837680T3 (en)
PT (2) PT2837680T (en)
SG (1) SG10201702537RA (en)
SI (2) SI2837680T1 (en)
WO (1) WO2013006479A2 (en)
ZA (1) ZA201309372B (en)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014109858A1 (en) * 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
WO2014159259A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US8895709B2 (en) 2008-10-20 2014-11-25 Abbvie Inc. Isolation and purification of antibodies using protein A affinity chromatography
US8906646B2 (en) 2006-09-13 2014-12-09 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2015105609A1 (en) 2014-01-13 2015-07-16 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9109010B2 (en) 2008-10-20 2015-08-18 Abbvie Inc. Viral inactivation during purification of antibodies cross reference to related applications
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9193787B2 (en) 2012-04-20 2015-11-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
WO2015188009A1 (en) 2014-06-04 2015-12-10 Amgen Inc. Methods for harvesting mammalian cell cultures
US9234033B2 (en) 2012-09-02 2016-01-12 Abbvie, Inc. Methods to control protein heterogeneity
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
JP2016514475A (en) * 2013-03-26 2016-05-23 コヒラス・バイオサイエンシズ・インコーポレイテッド Protein production method
WO2016089919A1 (en) 2014-12-01 2016-06-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
JP2016534732A (en) * 2013-10-31 2016-11-10 アムジエン・インコーポレーテツド Use of monensin to regulate glycosylation of recombinant proteins
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9550826B2 (en) 2013-11-15 2017-01-24 Abbvie Inc. Glycoengineered binding protein compositions
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
JP2017521057A (en) * 2014-06-09 2017-08-03 ジェンザイム・コーポレーション Seed train method and its use
WO2017149065A1 (en) 2016-03-02 2017-09-08 Lonza Ltd Improved fermentation process
JP2018500041A (en) * 2014-12-31 2018-01-11 エルジー・ケム・リミテッド Methods for regulating glycosylation of recombinant glycoproteins
US10047141B2 (en) 2014-01-30 2018-08-14 Coherus Biosciences, Inc. Method of manufacturing a protein by perfusion in media with a low amino acid concentration
US10213508B2 (en) 2011-10-18 2019-02-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with xylitol
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US10822429B2 (en) 2012-07-09 2020-11-03 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
US10947306B2 (en) 2012-09-11 2021-03-16 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US11060058B2 (en) 2014-06-06 2021-07-13 Genzyme Corporation Perfusion culturing methods and uses thereof
WO2022047108A1 (en) * 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
WO2022036275A3 (en) * 2020-08-14 2022-05-12 Bristol-Myers Squibb Company Manufacturing process for protein
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US11702628B2 (en) 2017-03-31 2023-07-18 Boehringer Ingelheim International Gmbh Perfusion medium for culturing mammalian cells and reducing cell bleed in a perfusion cell culture
WO2024054414A1 (en) 2022-09-06 2024-03-14 Amgen Inc. Lean perfusion cell culture methods
WO2024059235A2 (en) 2022-09-16 2024-03-21 Amgen Inc. A method for harvesting products from perfusion cultures
US12084686B2 (en) 2018-05-01 2024-09-10 Amgen Inc. Antibodies with modulated glycan profiles

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2837680T (en) * 2011-07-01 2020-07-10 Amgen Inc. Mammalian cell culture
JP6530171B2 (en) * 2014-09-09 2019-06-12 旭化成メディカル株式会社 Method of collecting culture product
CN105385731B (en) * 2015-12-25 2018-10-30 上海莱士血液制品股份有限公司 A kind of perfusion cultural method of eight factors of expression recombination
US20190048070A1 (en) * 2016-01-06 2019-02-14 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species and fragments in a monoclonal antibody composition
US11285210B2 (en) 2016-02-03 2022-03-29 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
WO2018178063A1 (en) * 2017-03-31 2018-10-04 Boehringer Ingelheim International Gmbh Perfusion medium
AU2018313950A1 (en) 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
US11609120B2 (en) 2017-10-06 2023-03-21 Lonza Ltd Automated control of cell culture using Raman spectroscopy
CA3075679A1 (en) 2017-10-16 2019-04-25 Regeneron Pharmaceuticals, Inc. Perfusion bioreactor and related methods of use
BR112020011215A2 (en) * 2017-12-08 2020-11-17 Juno Therapeutics Inc process for producing a modified t-cell composition
PT3818078T (en) * 2018-07-03 2024-04-18 Bristol Myers Squibb Co Methods of producing recombinant proteins
EP3906107A4 (en) * 2018-12-31 2023-02-22 Repligen Corporation Filter for mammalian cell culture perfusion and clarification with hydrophobic hollow fiber
CN114729306A (en) * 2019-09-27 2022-07-08 勃林格殷格翰国际公司 Concentrated perfusion medium
EP4217383A1 (en) 2020-09-22 2023-08-02 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
CN114574430A (en) * 2022-03-22 2022-06-03 成都博宠生物科技有限公司 Expi293F cell culture method
CN115287251A (en) * 2022-08-25 2022-11-04 无锡药明生物技术股份有限公司 Intermittent perfusion combined batch feeding culture
CN116790483B (en) * 2023-08-22 2023-10-20 苏州依科赛生物科技股份有限公司 CHO cell serum-free medium and application thereof

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695623A (en) 1982-05-06 1987-09-22 Amgen Consensus human leukocyte interferon
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
EP0367566A1 (en) 1988-10-31 1990-05-09 Immunex Corporation Interleukin-4 receptors
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
EP0460846A1 (en) 1990-06-05 1991-12-11 Immunex Corporation Type II interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
WO1994028391A1 (en) 1993-05-24 1994-12-08 Immunex Corporation Ligands for flt3 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
WO1997001633A1 (en) 1995-06-29 1997-01-16 Immunex Corporation Cytokine that induces apoptosis
US5610279A (en) 1989-09-12 1997-03-11 Hoffman-La Roche Inc. Human TNF receptor
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US5767064A (en) 1990-06-05 1998-06-16 Immunex Corporation Soluble type II interleukin-1 receptors and methods
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US6015938A (en) 1995-12-22 2000-01-18 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499064A (en) 1982-06-03 1985-02-12 Clayton Foundation For Research Assessment of nutritional status of individuals
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US5143842A (en) * 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
US7037721B1 (en) * 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
WO1998008934A1 (en) 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US20030036505A1 (en) 2000-09-25 2003-02-20 Human Genome Sciences, Inc. Signal transduction pathway component polynucleotides, polypeptides, antibodies and methods based thereon
CA2447791A1 (en) 2001-06-13 2002-12-19 Neslihan Delacruz Methods of culturing animal cells and polypeptide production in animal cells
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
ES2557741T3 (en) 2002-03-27 2016-01-28 Immunex Corporation Procedures to increase polypeptide production
CN1930281A (en) * 2004-03-05 2007-03-14 帝斯曼知识产权资产管理有限公司 Process for cell culturing by continuous perfusion and alternating tangential flow
CN1332024C (en) * 2004-06-09 2007-08-15 中国科学院大连化学物理研究所 3D culture method for micro carrier of sponge cell
ATE505219T1 (en) 2004-07-07 2011-04-15 Coloplast As CATHETER CONTAINING ESTANE 58212
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (en) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals Production of polypeptides
EP1812557A4 (en) * 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc Chemically defined media compositions
PL1885753T3 (en) * 2005-06-03 2011-12-30 Ares Trading Sa Production of recombinant Il-18 binding protein
DK2343362T4 (en) 2006-07-14 2024-07-08 Patheon Holdings I B V IMPROVED PROCEDURE FOR CULTIVATING CELLS
US20080206819A1 (en) * 2006-08-21 2008-08-28 Mary Tsao Intensified Perfusion Production Method
CA2668771C (en) 2006-11-08 2016-03-15 Wyeth Rationally designed media for cell culture
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
US20090042253A1 (en) 2007-08-09 2009-02-12 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
CA2734922C (en) 2008-09-15 2020-01-14 Laetitia Malphettes Compositions comprising polynucleotides comprising hybrid osmo-responsive transcriptional regulatory elements and methods for producing a protein under conditions of hyperosmolarity
CN101603026B (en) * 2009-06-19 2011-01-19 华东理工大学 Animal origin-free low-protein culture medium suitable for animal cell product production
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
BR122021005965B1 (en) 2009-07-31 2022-01-25 Baxalta Incorporated Method for producing a disintegrin and metalloproteinase composition with thrombospondin motif (adamts)
LT2464725T (en) 2009-08-11 2020-06-10 F. Hoffmann-La Roche Ag Production of proteins in glutamine-free cell culture media
EP3255153A1 (en) 2009-11-17 2017-12-13 E. R. Squibb & Sons, L.L.C. Methods for enhanced protein production
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
DK2635604T3 (en) * 2010-11-01 2017-02-27 Symphogen As PAN-HER-ANTIBODY COMPOSITION
US9133493B2 (en) * 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
LT2837680T (en) * 2011-07-01 2020-07-10 Amgen Inc. Mammalian cell culture
TWI625390B (en) 2013-03-14 2018-06-01 安美基公司 Methods for increasing mannose content of recombinant proteins
MX2016005572A (en) 2013-10-31 2016-12-09 Amgen Inc Use of monensin to regulate glycosylation of recombinant proteins.
CN108473945A (en) * 2015-11-17 2018-08-31 辉瑞公司 Culture medium and fermentation process for producing polysaccharide in bacterial cell culture

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695623A (en) 1982-05-06 1987-09-22 Amgen Consensus human leukocyte interferon
US4897471A (en) 1982-05-06 1990-01-30 Amgen Consensus human leukocyte interferon
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
EP0367566A1 (en) 1988-10-31 1990-05-09 Immunex Corporation Interleukin-4 receptors
US5856296A (en) 1988-10-31 1999-01-05 Immunex Corporation DNA encoding interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5610279A (en) 1989-09-12 1997-03-11 Hoffman-La Roche Inc. Human TNF receptor
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
EP0460846A1 (en) 1990-06-05 1991-12-11 Immunex Corporation Type II interleukin-1 receptors
US5767064A (en) 1990-06-05 1998-06-16 Immunex Corporation Soluble type II interleukin-1 receptors and methods
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
WO1994028391A1 (en) 1993-05-24 1994-12-08 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
WO1997001633A1 (en) 1995-06-29 1997-01-16 Immunex Corporation Cytokine that induces apoptosis
US6015938A (en) 1995-12-22 2000-01-18 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
"Animal cell culture: A Practical Approach", 1992, OXFORD UNIVERSITY PRESS
"Current Protocols in Molecular Biology", 1988, WILEY & SONS
"Growth Factors: A Practical Approach", 1993, OXFORD UNIVERSITY PRESS INC.
"Human Cytokines: Handbook for Basic and Clinical Research. all volumes", 1998, BLACKWELL SCIENCES
"Leukocyte Typine VI", 1996
"Remington's Pharmaceutictll Sciences", 1995, MACK PUBLISHING COMPANY
"The Cytokine Handbook", vol. 1, 2, ACADEMIC PRESS
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1992, GREENE PUBLISHING ASSOCIATES
BRASEL ET AL., BLOOD, vol. 88, 1996, pages 2004 - 2012
CHU; ROBINSON, CURRENT OPIN. BIOTECHNOL., vol. 12, 2001, pages 180 - 87
DO; CHEN-KIANG, CYTOKINE GROWTH FACTOR REV., vol. 13, no. 1, 2002, pages 19 - 25
FUREY, GEN. ENG. NEWS., vol. 22, no. 7, 2002, pages 62 - 63
HÅKANSSON ET AL., STRUCTURE, vol. 7, 1999, pages 255 - 64
HARBURY ET AL., NATURE, vol. 371, 1994, pages 80 - 83
HARBURY ET AL., SCIENCE, vol. 262, 1993, pages 1401 - 05
HARLOW; LANE: "Antibodies: A Laboratory Manual", 1990, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR
KAUFMAN ET AL., J. BIOL CHEM, vol. 263, 1988, pages 6352 - 6362
KAUFMAN R.J., METH ENZVMOL, vol. 185, 1990, pages 537 - 566
KAUFMAN, R.J., LARGE SCALE MAMMALIAN CELL CULTURE, 1990, pages 15 - 69
LOVEJOY ET AL., SCIENCE, vol. 259, 1993, pages 1288 - 1293
MAISONPIERRE ET AL., SCIENCE, vol. 277, no. 5322, 1997, pages 55 - 60
MCKINNON ET AL., J MOL ENDOCRINOL, vol. 6, 1991, pages 231 - 239
RUEGG; PYTELA, GENE, vol. 160, 1995, pages 257 - 62
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING LABORATORY PRESS
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
STETTLER, BIOTECHNOL BIOENG. DEC 20, vol. 95, no. 6, 2006, pages 1228 - 33
URLAUB ET AL., PROC NATL ACAD SCI USA, vol. 77, 1980, pages 4216 - 4220
VOISARD ET AL., BIOTECHNOLOGY AND BIOENGINEERING, vol. 82, 2003, pages 751 - 65
WOOD ET AL., J. IMMUNOL., vol. 145, 1990, pages 3011 - 3016

Cited By (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10119118B2 (en) 2006-09-13 2018-11-06 Abbvie Inc. Modified serum-free cell culture medium
US8906646B2 (en) 2006-09-13 2014-12-09 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US9090867B2 (en) 2006-09-13 2015-07-28 Abbvie Inc. Fed-batch method of making anti-TNF-alpha antibody
US9234032B2 (en) 2006-09-13 2016-01-12 Abbvie Inc. Fed-batch methods for producing adalimumab
US9284371B2 (en) 2006-09-13 2016-03-15 Abbvie Inc. Methods of producing adalimumab
US9073988B2 (en) 2006-09-13 2015-07-07 Abbvie Inc. Fed batch method of making anti-TNF-alpha antibodies
US9109010B2 (en) 2008-10-20 2015-08-18 Abbvie Inc. Viral inactivation during purification of antibodies cross reference to related applications
US8895709B2 (en) 2008-10-20 2014-11-25 Abbvie Inc. Isolation and purification of antibodies using protein A affinity chromatography
US9018361B2 (en) 2008-10-20 2015-04-28 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
US9090688B2 (en) 2011-04-27 2015-07-28 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9255143B2 (en) 2011-04-27 2016-02-09 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9365645B1 (en) 2011-04-27 2016-06-14 Abbvie, Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9505834B2 (en) 2011-04-27 2016-11-29 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US10213508B2 (en) 2011-10-18 2019-02-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with xylitol
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US11000588B2 (en) 2011-10-18 2021-05-11 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US11129876B2 (en) 2011-10-18 2021-09-28 Coherus Biosciences, Inc. Etanercept formulations stabilized with amino acids
US10293049B2 (en) 2011-10-18 2019-05-21 Coherus Biosciences, Inc. Etanercept formulations stabilized with amino acids
US10772963B2 (en) 2011-10-18 2020-09-15 Coherus Biosciences, Inc. Etanercept formulations stabilized with xylitol
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9957318B2 (en) 2012-04-20 2018-05-01 Abbvie Inc. Protein purification methods to reduce acidic species
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9683033B2 (en) 2012-04-20 2017-06-20 Abbvie, Inc. Cell culture methods to reduce acidic species
US9193787B2 (en) 2012-04-20 2015-11-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9708400B2 (en) 2012-04-20 2017-07-18 Abbvie, Inc. Methods to modulate lysine variant distribution
US9359434B2 (en) 2012-04-20 2016-06-07 Abbvie, Inc. Cell culture methods to reduce acidic species
US9346879B2 (en) 2012-04-20 2016-05-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US10822429B2 (en) 2012-07-09 2020-11-03 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
US9234033B2 (en) 2012-09-02 2016-01-12 Abbvie, Inc. Methods to control protein heterogeneity
US9290568B2 (en) 2012-09-02 2016-03-22 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US10954295B2 (en) 2012-09-11 2021-03-23 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US10954293B2 (en) 2012-09-11 2021-03-23 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US10954294B2 (en) 2012-09-11 2021-03-23 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US11001627B2 (en) 2012-09-11 2021-05-11 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US10947306B2 (en) 2012-09-11 2021-03-16 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
WO2014109858A1 (en) * 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US9822388B2 (en) 2013-03-14 2017-11-21 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US11319568B2 (en) 2013-03-14 2022-05-03 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US11952605B2 (en) 2013-03-14 2024-04-09 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
TWI625390B (en) * 2013-03-14 2018-06-01 安美基公司 Methods for increasing mannose content of recombinant proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
EP4141104A1 (en) 2013-03-14 2023-03-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US11459595B2 (en) 2013-03-14 2022-10-04 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014159259A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Methods for increasing mannose content of recombinant proteins
EP3434760A1 (en) 2013-03-14 2019-01-30 Amgen, Inc Methods for increasing mannose content of recombinant proteins
US9708399B2 (en) 2013-03-14 2017-07-18 Abbvie, Inc. Protein purification using displacement chromatography
AU2014241259B2 (en) * 2013-03-26 2018-12-06 Coherus Biosciences, Inc. Protein production method
JP2016514475A (en) * 2013-03-26 2016-05-23 コヒラス・バイオサイエンシズ・インコーポレイテッド Protein production method
EP2978498A4 (en) * 2013-03-26 2016-10-05 Coherus Biosciences Inc Protein production method
AU2014241259B9 (en) * 2013-03-26 2018-12-20 Coherus Biosciences, Inc. Protein production method
AU2019201129B2 (en) * 2013-03-26 2020-12-24 Coherus Biosciences, Inc. Protein production method
US10975138B2 (en) 2013-03-26 2021-04-13 Coherus Biosciences, Inc. Correctly folded etanercept composition
EP3391942A1 (en) * 2013-03-26 2018-10-24 Coherus Biosciences, Inc. Protein production method
US10894972B2 (en) 2013-05-30 2021-01-19 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US11597959B2 (en) 2013-05-30 2023-03-07 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US11434514B2 (en) 2013-05-30 2022-09-06 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US11946085B2 (en) 2013-05-30 2024-04-02 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US10421987B2 (en) 2013-05-30 2019-09-24 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US10184143B2 (en) 2013-05-30 2019-01-22 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9266949B2 (en) 2013-10-18 2016-02-23 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9200069B2 (en) 2013-10-18 2015-12-01 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9499616B2 (en) 2013-10-18 2016-11-22 Abbvie Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9315574B2 (en) 2013-10-18 2016-04-19 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9200070B2 (en) 2013-10-18 2015-12-01 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9522953B2 (en) 2013-10-18 2016-12-20 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9688752B2 (en) 2013-10-18 2017-06-27 Abbvie Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
JP2016534732A (en) * 2013-10-31 2016-11-10 アムジエン・インコーポレーテツド Use of monensin to regulate glycosylation of recombinant proteins
US9550826B2 (en) 2013-11-15 2017-01-24 Abbvie Inc. Glycoengineered binding protein compositions
EP3083933A1 (en) * 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
US11254963B2 (en) 2014-01-13 2022-02-22 Amgen Inc. Increasing ornithine accumulation to increase high mannose glycoform content of recombinant proteins
US10513723B2 (en) 2014-01-13 2019-12-24 Amgen Inc. Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins
WO2015105609A1 (en) 2014-01-13 2015-07-16 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
US10047141B2 (en) 2014-01-30 2018-08-14 Coherus Biosciences, Inc. Method of manufacturing a protein by perfusion in media with a low amino acid concentration
US11001623B2 (en) 2014-01-30 2021-05-11 Coherus Biosciences, Inc. Method of manufacturing a protein by perfusion in media with a low amino acid concentration
JP2017519497A (en) * 2014-06-04 2017-07-20 アムジエン・インコーポレーテツド Method for recovering mammalian cell culture
WO2015188009A1 (en) 2014-06-04 2015-12-10 Amgen Inc. Methods for harvesting mammalian cell cultures
JP7377316B2 (en) 2014-06-04 2023-11-09 アムジエン・インコーポレーテツド Methods for harvesting mammalian cell cultures
EP3926051A1 (en) 2014-06-04 2021-12-22 Amgen, Inc Methods for harvesting mammalian cell cultures
JP2020124207A (en) * 2014-06-04 2020-08-20 アムジエン・インコーポレーテツド Methods for harvesting mammalian cell cultures
EP4372078A2 (en) 2014-06-04 2024-05-22 Amgen Inc. Methods for harvesting mammalian cell cultures
US11384378B2 (en) 2014-06-04 2022-07-12 Amgen Inc. Methods for harvesting mammalian cell cultures
JP2022126811A (en) * 2014-06-04 2022-08-30 アムジエン・インコーポレーテツド Methods for harvesting mammalian cell cultures
US11427848B2 (en) 2014-06-04 2022-08-30 Amgen Inc. Methods for harvesting mammalian cell cultures
JP7097404B2 (en) 2014-06-04 2022-07-07 アムジエン・インコーポレーテツド Methods for Retrieving Mammalian Cell Cultures
US12006510B2 (en) 2014-06-06 2024-06-11 Genzyme Corporation Perfusion culturing methods and uses thereof
US11060058B2 (en) 2014-06-06 2021-07-13 Genzyme Corporation Perfusion culturing methods and uses thereof
JP2017521057A (en) * 2014-06-09 2017-08-03 ジェンザイム・コーポレーション Seed train method and its use
EP3152299B1 (en) 2014-06-09 2019-11-20 Genzyme Corporation Seed train processes and uses thereof
WO2016089919A1 (en) 2014-12-01 2016-06-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
US10167492B2 (en) 2014-12-01 2019-01-01 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
US10822630B2 (en) 2014-12-01 2020-11-03 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
EP3680344A1 (en) 2014-12-01 2020-07-15 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
EP3227454B1 (en) 2014-12-01 2020-01-29 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
US10131891B2 (en) 2014-12-31 2018-11-20 Lg Chem, Ltd. Method of using insulin for controlling glycosylation of recombinant glycoprotein
JP2018500041A (en) * 2014-12-31 2018-01-11 エルジー・ケム・リミテッド Methods for regulating glycosylation of recombinant glycoproteins
IL261411B2 (en) * 2016-03-02 2024-03-01 Lonza Ag Improved fermentation process
IL261411B1 (en) * 2016-03-02 2023-11-01 Lonza Ag Improved fermentation process
US11377677B2 (en) 2016-03-02 2022-07-05 Lonza Ltd Fermentation process
WO2017149065A1 (en) 2016-03-02 2017-09-08 Lonza Ltd Improved fermentation process
US11702628B2 (en) 2017-03-31 2023-07-18 Boehringer Ingelheim International Gmbh Perfusion medium for culturing mammalian cells and reducing cell bleed in a perfusion cell culture
US12084686B2 (en) 2018-05-01 2024-09-10 Amgen Inc. Antibodies with modulated glycan profiles
WO2022036275A3 (en) * 2020-08-14 2022-05-12 Bristol-Myers Squibb Company Manufacturing process for protein
WO2022047108A1 (en) * 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
WO2024054414A1 (en) 2022-09-06 2024-03-14 Amgen Inc. Lean perfusion cell culture methods
WO2024059235A2 (en) 2022-09-16 2024-03-21 Amgen Inc. A method for harvesting products from perfusion cultures

Also Published As

Publication number Publication date
KR20160075814A (en) 2016-06-29
AU2018203972B2 (en) 2020-09-17
HK1206057A1 (en) 2015-12-31
AU2012279230B2 (en) 2016-08-18
CL2016001190A1 (en) 2017-06-09
DK2726600T3 (en) 2017-05-15
ES2625045T3 (en) 2017-07-18
SG10201702537RA (en) 2017-04-27
ZA201309372B (en) 2014-08-27
KR102358951B1 (en) 2022-02-08
IL278430B (en) 2022-01-01
IL297998A (en) 2023-01-01
HUE049119T2 (en) 2020-09-28
AU2020281075B2 (en) 2022-12-22
US20140255993A1 (en) 2014-09-11
AU2018203972A1 (en) 2018-06-21
JP2014520534A (en) 2014-08-25
ES2788132T3 (en) 2020-10-20
US11685772B2 (en) 2023-06-27
IL310968A (en) 2024-04-01
IL297998B2 (en) 2024-07-01
CN107988166B (en) 2022-03-15
LT2726600T (en) 2017-05-25
KR20240005106A (en) 2024-01-11
US11292829B2 (en) 2022-04-05
WO2013006479A3 (en) 2013-03-28
EA039023B1 (en) 2021-11-23
PT2726600T (en) 2017-04-24
US11827692B2 (en) 2023-11-28
MX351974B (en) 2017-11-06
PT2837680T (en) 2020-04-17
SI2837680T1 (en) 2020-07-31
IL297998B1 (en) 2024-03-01
KR20230114317A (en) 2023-08-01
IL288509B (en) 2022-12-01
KR102108663B1 (en) 2020-05-07
AU2012279230A1 (en) 2014-01-09
CA2952347A1 (en) 2013-01-10
KR101662412B1 (en) 2016-10-04
IL229803B (en) 2020-11-30
EP2837680A1 (en) 2015-02-18
KR101857380B1 (en) 2018-05-11
US20230117598A1 (en) 2023-04-20
EA201391826A1 (en) 2014-04-30
DK2837680T3 (en) 2020-04-27
HK1197081A1 (en) 2015-01-02
JP5897708B2 (en) 2016-03-30
CN107988166A (en) 2018-05-04
EP2837680B1 (en) 2020-02-26
CN103827292B (en) 2018-01-26
BR122021007265B1 (en) 2022-02-22
KR20180050433A (en) 2018-05-14
CA2838695A1 (en) 2013-01-10
BR112013033730B1 (en) 2022-01-25
US20230129523A1 (en) 2023-04-27
KR20200051046A (en) 2020-05-12
CY1118863T1 (en) 2018-01-10
PL2837680T3 (en) 2020-08-10
SI2726600T1 (en) 2017-07-31
CY1123146T1 (en) 2021-12-31
US20230227535A1 (en) 2023-07-20
PL2726600T3 (en) 2017-08-31
KR20220021008A (en) 2022-02-21
US20200407427A1 (en) 2020-12-31
US20220185869A1 (en) 2022-06-16
KR20140031375A (en) 2014-03-12
US11673941B2 (en) 2023-06-13
MX2013014937A (en) 2014-04-16
KR102558247B1 (en) 2023-07-24
IL288509B2 (en) 2023-04-01
CL2013003792A1 (en) 2014-07-25
IL288509A (en) 2022-01-01
LT2837680T (en) 2020-07-10
EP2726600B1 (en) 2017-02-15
HUE033279T2 (en) 2017-11-28
US11634476B2 (en) 2023-04-25
BR112013033730A2 (en) 2017-01-31
CN103827292A (en) 2014-05-28
CA2838695C (en) 2017-02-14
EP2726600A2 (en) 2014-05-07
AU2023201127A1 (en) 2023-03-30
AU2016244255A1 (en) 2016-10-27
US20210061888A1 (en) 2021-03-04
AU2020281075A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
AU2020281075B2 (en) Mammalian cell culture
WO2014159259A1 (en) Methods for increasing mannose content of recombinant proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12738674

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2838695

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/014937

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2014519184

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201391826

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2013003792

Country of ref document: CL

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012279230

Country of ref document: AU

Date of ref document: 20120629

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147001985

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2012738674

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012738674

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14127050

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013033730

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013033730

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20131227